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1. ABBREVIATIONS 
    
X                                                               AIEX       Anion exchange 
BAE      Bovine aortic endothelial cells 
BM      Basement membrane 
BSA      Bovine serum albumin 
CIEX      Cation exchange 
CIP      Calf intestinal phosphatase 
CMV      Cytomegalovirus 
EC       Extracellular 
EpoR      Erythropoietin receptor 
FGF-1      Fibroblast growth factor 
FL      Full-length 
GEH      GE Healthcare 
H6, H8, His-6, His-8    Tag of 6 or 8 histidines 
HPLC      High performance liquid chromatography 
HSPGs     Heparin sulphate proteoglycans 
HUVEC      Human umbilical cord vein endothelial cells 
hVEGF-D     human VEGF-D 
IL-3      Interleukin-3 
K14      keratin 14  
LEC      Lymphatic endothelial cell 
mVEGF-D     murine VEGF-D 
NRP-1/-2     Neuropilin -1/-2 
o/n       Over night 
PAE      Porcine aortic endothelial 
PAS      Protein A sepharose 
PBS       Phosphate-buffered saline 
PCR       Polymerase chain reaction 
PDGF      Platelet derived growth factor 
PlGF      Placenta growth factor 
rhVEGF-D     recombinant human VEGF-D 
RT      Room temperature 
RTK      Receptor tyrosine kinase 
S2      Drosophila melanogaster Schneider cell line 2 
SAB       Supernatant after binding 
SD      Standard deviation 
SEC       Size exclusion chromatography 
Sup Insect cell supernatant, conditioned insect cell 
media 
svVEGF     snake venom VEGF 
TBS       Tris-buffered saline 
VEGF      Vascular endothelial growth factor 
VEGF-D???C/VEGF-DdNdC Fully processed form of VEGF-D, mature 
VEGF-D  
VEGFR     Vascular endothelial growth factor receptor 
VHD      VEGF homology domain 
VPF Vascular permeability factor (aka VEGF, 
VEGF-A) 
VRF      VEGF related factor (aka VEGF-B) 
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2. INTRODUCTION 
 
2.1 The vascular system 
In animals larger than 1 mm in diameter, transport by diffusion is inadequate for survival. 
Circulatory systems have evolved to meet the requirements of transporting metabolic 
reagents, gases, cells and information throughout the body. The mammalian circulatory 
system comprises the blood vascular system and the lymphatic vascular system. 
 
A heart and blood vessels from arteries and veins to capillaries form the mammalian blood 
circulatory system. The transfer of respiratory gases, nutrients, waste products, hormones, 
antibodies, cells and other materials between blood and tissues occurs mainly in capillaries 
(Randall et al., 2002).  
 
A major function of the lymphatic system is to transport fluid, plasma proteins and cells 
which have escaped from the blood capillaries back to the blood circulation via the 
lymphatic capillaries, the collecting lymphatic vessels and the thoracic duct. The lymphatic 
system also has a crucial role in immune defence, since it filters lymph and its antigens in the 
lymphnodes. In the small intestine, the lymphatics serve a specialized function in the 
absorption of dietary fat (Stone and Hugo, 1972; lymphatic system reviewed in Witte et al., 
2001). 
 
2.1.1 Development of the vascular system 
During embryogenesis the cardiovascular system is the first functional organ system 
(Gilbert, 1991) and its development and growth are essential for maintaining the growth of 
the  whole  embryo.  Vascular  development  is  a  complex  series  of  events  during  which  
endothelial cells, that form the inner lining of all blood and lymphatic vessels and heart 
endocardium, differentiate, proliferate, migrate and undergo maturation into an organized 
network of vessels (Reviewed in Baldwin, 1996).  
 
2.1.1.1 Vasculogenesis and angiogenesis 
The mesodermal precursors for endothelial cells and blood cells are called angioblasts or 
hemangioblasts (His, 1900). In vasculogenesis, angioblasts aggregate first into blood islands 
and later assemble into a primitive vascular network (Coffin et al., 1991; Coffin and Poole, 
1988; Risau, 1997; Risau and Flamme, 1995). These primitive vessels are then extensively 
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remodelled into arteries, veins and capillaries in a process called angiogenesis. Angiogenesis 
consists of sprouting, splitting and fusion of pre-existing vessels to adjust the vascular 
density according to the metabolic requirements of a certain tissue or organ (Carmeliet, 
2000; Risau 1997).  
Soon after the formation of vessels, endothelial cells become surrounded by basement 
membrane  (BM),  pericytes  or  vascular  smooth  muscle  cells.  BM  is  a  thin  sheet-like  
extracellular matrix which is mainly constructed of fibronectin, laminin, collagens and 
heparin sulphate proteoglycans (HSPGs). However, the composition varies depending on the 
type of the vessel. Failure to form a proper BM can lead to vessel instability, indicating an 
important role for the BM in normal vascular development (Beltramo et al., 2002; Thyboll et 
al., 2002). 
 
 
 
2.1.1.2. Lymphangiogenesis 
The lymphatic vessels arise after the establishment of the blood circulatory system.  Two 
theories about the development of the lymphatic vessels were proposed in the beginning of 
last century. The first suggested that lymphatic vessels are formed by sprouting from the 
lymph sacs, which themselves are formed by endothelial cells sprouting from the veins 
(Sabin, 1902). The second theory postulated that lymphatic structures arise by de novo 
formation of primary lymph sacs in the mesenchyme (Huntington, 1908; McClure, 1908; 
Kampmeier, 1912). Most evidence supports the first theory (Dumont et al., 1998; Wigle and 
Figure 1. Schematic 
representation of the maturation 
and stabilization of blood vessels. 
Growth factors and their receptors 
guiding these processes are shown 
in the arrow, and will be discussed 
later in chapters 1.2 and 1.3. The 
arteries are shown in red and the 
veins in blue. (Adapted from 
http://www.embryology.ch/francais/
pcardio/gefassegrundlage01.html#bl
utgefassentwicklung, 2006) 
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Oliver, 1999; Wigle et al., 2002), but also reports supporting the second theory have been 
published (Schneider, 1999; Papoutsi et al., 2001), suggesting that lymphatic development 
may require both mechanisms. The secondary lymphoid organs, for example lymph nodes, 
are superimposed on the lymphatic vessels. The lymph nodes initially develop when 
connective tissue starts to protrude into the sprouting lymph sacs. Thereafter the secondary 
lymphoid organs develop sequentially (Mebius, 2003).  
 
 
 
The lymphatic vasculature complements the blood vascular network, but rather than forming 
a circulatory system, the lymphatic network comprises a tree-like hierarchy of vessels that 
transports extravasated fluid and macromolecules unidirectionally from tissues back to the 
blood circulation (Witte, 2001). The lymphatic capillaries are blind-ended vessels with a 
single, thin, non-fenestrated lymphatic endothelial cell (LEC) layer. The basement 
membrane of the lymphatic vessels is incomplete; LECs have overlapping intercellular 
junctions and are anchored to the extracellular matrix through elastic fibers, which keep the 
vessels from collapsing during changes of interstitial pressure (Witte et al., 1997). Larger 
vessels have smooth muscle cell coverage and possess an intrinsic contractility which helps 
Figure 2. Schematic 
representation of the devel- 
opment of mammalian 
lymphatic vasculature. 
 LEC stands for lymphatic 
endothelial cells and E9.0-
E14.5 signify the days after 
fertilization (embryonic  
days) in mice when a certain 
developmental process has 
been observed to take place. 
Growth factors guiding 
differentiation and sprouting 
and signals specific to LECs 
are also shown. Some of 
these molecules will be 
covered in chapters 1.2 and 
1.3. (Adapted from Oliver 
and Alitalo, 2005.)   
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to pump the lymph fluid forward. The lymph flow is also sustained by arterial pulsation and 
skeletal muscle movements while the luminal valves prevent backflow. 
  
2.1.2 Adulthood angiogenesis and lymphangiogenesis  
After the embryonic and postnatal development, the endothelial cell proliferation is 
downregulated, but the cells maintain their ability to divide. Throughout adult life, 
angiogenesis has an important role in physiological processes such as the female 
reproductive cycle and in tissue growth and repair. Angiogenesis also occurs in the heart in 
response to exercise (Folkman et al., 1992). During normal, physiological angiogenesis the 
neovascularisation is short lived and controlled but in certain pathological conditions, such 
as in cancer and in chronic inflammatory disorders, the neovascularisation is sustained, and 
excessive angiogenesis contributes to the disease development (reviewed in Carmeliet & 
Jain, 2000 and Folkman, 1992, 1995).  
 
As well as angiogenesis, also lymphangiogenesis occurs in adults. In wound healing, 
lymphatics sprout from pre-exsisting lymphatic capillaries into granulation tissue, somewhat 
lagging behind angiogenesis; and soon after their formation, the lymphatic vessels tend to 
regress (Clark ER and Clark EL, 1932; Paavonen et al., 2000).   
 
2.1.3 Pathological conditions involving blood and lymphatic vessels 
Insufficient or excessive angiogenesis and/or lymphangiogenesis contributes to several 
diseases.  The  ability  to  control  the  growth  of  vessels  could  provide  strategies  for  the  
treatment of such conditions. 
 
2.1.3.1 Angiogenesis in diseases 
Pathological angiogenesis, the excess neovascularisation of tissues, occurs in many different 
conditions. For example, the chronic inflammation in rheumatoid arthritis is sustained due to 
excessive angiogenesis. This, in turn, is caused by production of proangiogenic factors by 
infiltrating macrophages and inflammatory cells. Angiogenesis mediates pathogenesis also in 
ocular neovascularisation and skin diseases such as psoriasis (reviewed in Folkman, 1995). 
In addition, angiogenesis has a major role in cancer progression, which will be discussed in 
detail below. In the above mentioned conditions, inhibition of angiogenesis could be an 
efficient treatment option.   
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On the other hand, lack of angiogenesis complicates certain diseases like duodenal ulcer, 
ischemic heart disease and peripheral vascular disease. In these conditions, stimulation of 
angiogenesis might be a strategy to accelerate healing.  
 
2.1.3.2 Tumor angiogenesis 
Tumor cells are often undifferentiated cells which overexpress several growth factors and 
growth factor receptors which can stimulate their own growth. Tumors cannot grow beyond 
the size of a few cubic millimetres without sufficient supply of oxygen and nutrients 
(Folkman, 1971; Folkman, 1995). Therefore tumor cells need to stimulate endothelial cells to 
proliferate and migrate towards the tumor, which leads to the vascularisation of the tumor 
(Gimbrone et al., 1972). Luckily, only a small percentage of human tumors are thought to 
switch to the angiogenic phenotype. Various signals, such as metabolic and mechanical 
stress, immune/inflammatory response and genetic mutations can trigger this switch 
(reviewed in Carmeliet and Jain, 2000).   
 
Tumor vascular vessels are highly disorganized, tortuous and dilated with uneven diameter, 
excessive branching, shunts and incomplete or absent muscular and BM coverage (Carmeliet 
and Jain, 2000). Consequently, tumor vessels are leaky and blood flow is variable, 
contributing to increased interstitial tumor pressure and impaired delivery of therapeutic 
agents into tumors (Jain and Carmeliet, 2001). 
 
Although metastasis via lymphatic vessels is more common, metastatic spread of tumor cells 
can occur via blood vessels (hematogenous metastasis). In some models, metastatic spread to 
lymph nodes occurred in the absence of tumor lymphangiogenesis, probably via preexisting 
lymphatic vessels, indicating that the role of angiogenesis and lymphangiogenesis for 
metastasis may vary depending on the tumor type (Wong et al., 2005). It will be important in 
the future to define which tumors are dependent on (lymph-) angiogenesis for metastatic 
spread and which are the molecular mechanisms required for these processes. Metastasis is 
one of the leading causes of death in cancer patients (Plate, 2001). Inhibition of tumor 
angiogenesis is considered to be one of the most promising therapeutic strategies to inhibit 
tumor growth. Presumably anti-angiogenic therapies can act on any solid tumor type, do not 
induce tumor cell resistance and should not affect normal tissues (Plate, 2001).  
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2.1.3.3 Lymphangiogenesis in diseases 
Lymphedema is an imbalance between lymph formation and absorption into lymphatic 
vessels; fluid accumulates in the tissues increasing interstitial pressure which leads to 
disfiguring and disabling swelling of the extremities, tissue fibrosis, adipose tissue 
generation, poor immune function and susceptibility to infections as well as impaired wound 
healing. Secondary or acquired lymphedema develops when lymphatic vessels are damaged 
for example by surgery or radiation therapy or obstructed by parasitic infection (Lymphatic 
filariasis) (Witte et al., 1997). In contrast, hereditary or primary lymphedema (e.g. Milroy’s 
disease) is usually due to absent or insufficiently developed superficial or subcutaneous 
lymplatic vessels. In some families, the genetic mutation causing lymphedema has been 
recognized (Kärkkäinen et al., 2004) but primary lymphedemas are a heterogenous group of 
disorders. Identification of genetic markers and high-risk members of lymphedema families 
would facilitate the identification and management of the disease. 
 
2.1.3.4 Tumor lymphangiogenesis 
Compared to what we know about the tumor blood vasculature, little is known about the 
biology of the lymphatic vessels in tumors. Lymphatic vessels in the tumor periphery are 
known to contribute to tumor metastasis. These peritumoral lymphatic vessels have been 
documented enlarged and perfused (Jain and Fenton, 2002). Enlarged lymphatics may collect 
interstitial fluid and deattached cancer cells from the tumor surface, and thus facilitate tumor 
metastasis. However, it is still unresolved whether there are functional lymphatic vessels 
inside tumors (Jain and Fenton, 2002).  Intratumoral lymphatic vessels have been 
documented in certain types of tumors (Karpanen et al., 2001; Skobe et al., 2001; Stacker et 
al., 2001; Jackson et al., 2001) but haven’t been found in other types (Jackson et al., 2001; 
Mandriota et al., 2001). The capability of intratumoral lymphatics to function in the high 
interstitial pressure inside the tumor is still debated. In all, the interstitial hypertension 
complicates the delivery of therapeutic agents to tumors (Carmeliet and Jain, 2000). Looking 
from this point of view, tumor lymphangiogenesis might be good for chemotherapy.  
 
Because lymphatic vessels are more permeable than the blood vessels (Leak, 1976), it is 
believed that tumor cells enter the lymphatic vessels rather than the blood circulation. Tumor 
metastasis involves a series of complex processes that include the detachment of tumor cells 
from the primary tumor mass, access into lymphatic and blood vessels, exit from the vessels, 
and growth in secondary sites. Tumor cells spread via the lymphatic vessels to lymph nodes, 
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and eventually via blood vessels to distant organs (reviewed in Alitalo et al. 2005). Life 
expectancy of patients with malignant tumors is largely determined by metastatic 
dissemination. Thus, uncovering the mechanisms of metastasis could provide clues for an 
efficient treatment.  
 
 
 
 
2.2 Molecular regulation of vascular development  
Coordinated behaviour of cells, including growth and differentiation into specific tissues 
requires intercellular and cell-matrix signalling. Complex signalling mechanisms have 
evolved in multicellular organisms to guide the behaviour of individual cells. Messages 
between cells can be exchanged via signalling molecules. Long-range (endocrine) signalling 
Figure 3. Metastasis. Tumor cells spread via lymphatic vessels 
and blood vessels. Adapted from http://www.abpi.org.uk/ 
publications/publication_details/targetbreastcancer/q&a5.asp, 
2006 
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molecules are released into the circulation, and they can modify the behaviour of physically 
remote cell types. Classical hormones act as endocrines. Short-range (paracrine) signals, for 
example growth factors, act locally within tissues. 
   
2.2.1 Growth factors 
Growth factors are proteins that can stimulate the proliferation and/or differentiation of 
particular cells. Secreted growth factors usually diffuse relatively short distances in the 
extracellular matrix until they encounter their receptors on the surface on target cells. On the 
other  hand,  some growth  factors  bind  to  the  pericellular  matrix  or  are  anchored  to  the  cell  
surface and require close cell-cell contacts in order to bind to and activate their receptors on 
the neighbouring cells. Unlike hormones, most growth factors are synthesized by a variety of 
cell types rather than in specialized endocrine glands.  
 
Specificity  and  complexity  of  signalling  are  achieved  already  with  small  numbers  of  
molecules: one growth factor can act as a ligand for many different receptors and vice versa. 
Moreover, binding of a particular growth factor to a particular receptor on different cells can 
lead to different reactions depending on the developmental history and downstream 
signalling cascades of these cells.  
 
2.2.2 Receptors 
The receptors of growth factors have a ligand-binding extracellular domain, a single 
hydrophobic transmembrane region and a cytoplasmic portion. In many cases the 
cytoplasmic side of the receptor is a tyrosine kinase. These receptors, called receptor tyrosine 
kinases (RTKs), dimerize or oligomerize in response to ligand binding (Van der Geer et al., 
1994). This leads to auto- or crossphosphorylation of the RTK as well as the phosphorylation 
of other signalling molecules on specific tyrosine residues (Hubbard 1997; Lemmon and 
Schlessinger, 1994). As a result, intracellular signalling cascades are initiated. Generally the 
activation of intracellular signalling cascades eventually modifies the activity of transcription 
factors which reprogram gene expression.  
 
2.2.3 Regulation of vascularisation 
Regulatory agents are molecules that have a stimulatory or inhibitory effect on endothelial 
cells. There are both directly and indirectly acting factors. Directly acting factors bind to 
receptors on endothelial cells. Indirectly acting factors stimulate non-endothelial cells (for 
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example macrophages) to produce directly acting factors, which in turn stimulate endothelial 
cells (Müller et al., 1987).  
 
Inhibitors of angiogenesis are often parts of larger molecules that are cleaved proteolytically 
and become thereby activated. The regulation of angiogenesis is similar to the action of the 
blood clotting cascade; rapid and spatially limited response is achieved by cleaving off large 
amounts of inhibitors and inducers from inactive precursors (O’Reilly et al., 1994). 
Angiogenesis occurs when the “angiogenic switch” is on, that is when the effect of 
proangiogenic molecules is stronger than that of antiangiogenic molecules (Carmeliet and 
Jain, 2000; Hanahan and Folkman, 1996).  
 
A number of signal transduction systems are involved in vascularisation processes, including 
vascular endothelial growth factors (VEGFs)/VEGF-receptors, angiopoietin/Tie-receptors, 
platelet-derived growth factors (PDGFs)/PDGF-receptors and EphrinB2/EphB4 (Davis et al., 
1996; Ferrara et al., 1997; Heldin et al., 1999; Wang et al., 1998). Among these, VEGF and 
its receptors are key regulators of vasculogenesis as well as angiogenesis and 
lymphangiogenesis. 
 
 
 
 
2.3 The vascular endothelial growth factor (VEGF) family 
Members of the VEGF family belong to the cystine knot growth factor superfamily. All 
VEGFs  contain  an  approximately  100-amino-acid  VEGF  homology  domain  (VHD)  that  is  
characterized by the precise spacing of 8 cystine residues involved in intramolecular and 
Figure 4. An angiogenic 
stimulus induces endothelial 
cell differentiation, 
proliferation and  
migration.  
(Adapted from  
http://www.med.unibs.it/~airc/an
gio2.gif, 2006) 
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intermolecular disulfide bonds. This cystine knot motif is essential for establishing the 
tertiary structure of the subunits (McDonald et al., 1993). In addition to these conserved 
cystine residues, many other amino acids are conserved within the VHD. VEGFs are 
secreted as dimeric glycoproteins, and some can form heterodimers with each other. The 
family  has  seven  members;  VEGF-A,  placenta  growth  factor  (PlGF),  VEGF-B,  VEGF-C,  
VEGF-D, VEGF-Es and snake venom VEGF (svVEGF), discovered in respective order. 
VEGFs bind to their receptors, VEGFRs, on endothelial cells and stimulate cell growth. The 
main isoforms of  VEGF-A, VEGF-B, VEGF-C, VEGF-D and PlGF are encoded by seven 
exons and variation is produced by alternative mRNA splicing and proteolytic processing. 
The isoforms differ in their binding affinities to VEGF-receptors, coreceptors and 
extracellular matrix. The general binding patterns of VEGFs are shown in Figure 5.  
 
 
 
 
 
 
 
 
Figure 5.   The inter-
actions of VEGF family 
members with their 
receptors, the receptor 
tyrosine kinases VEGFR-
1, VEGFR-2 and 
VEGFR-3. VEGFR-1 
occurs also as a soluble 
form denoted  sVEGFR1. 
Neuropilins (NRP-1 and 
NRP-2) act as co-receptors 
for VEGFs. The binding 
pattern of the VEGFs to 
their receptors and co-
receptors is indicated by 
arrows. PM;  
plasma membrane. 
Adapted from Shibuya and 
Claesson-Welsh, 2005. 
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2.3.1 VEGF-A 
VEGF-A (also called VEGF or vascular permeability factor,  VPF) is  secreted by nearly all  
cells and it is the major inducer of angiogenesis in normal and pathological conditions 
(Dvorak et al., 1995; Carmeliet et al., 1996; Ferrara et al., 1996; Ferrara, 1997). It promotes 
endothelial cell proliferation, migration and tube formation and regulates vascular 
permeability (Dvorak et al., 1995; Klagsbrun and D’amore, 1996; Ferrara, 1997). VEGF-A is 
essential for embryonic vasculogenesis and angiogenesis (Carmeliet et al., 1996; Ferrara et 
al., 1996) and it acts as a survival factor for endothelial cells of newly formed vessels. Via its 
capability to recruit macrophages (Ferrara et al., 2003), VEGF-A can indirectly promote 
lymphangiogenesis (Cursiefen et al., 2004). In addition, VEGF-A plays an important role in 
tumor angiogenesis (Kim et a.l, 1993; Saleh et al., 1996). VEGF-A is upregulated in hypoxia 
(lack of oxygen in tissues) and downregulated in hyperoxia (Pugh et al., 2003), meaning that 
tissues can adjust their oxygen level by regulating vessel growth and regression.  
 
2.3.2 PlGF 
PlGF was originally discovered from, and is primarily expressed in the human placenta but it 
is also detected in thyroid gland, heart, lung, skeletal muscle and several tumors (Maglione et 
al., 1991; Persico et al., 1999). Compared with VEGF-A, its mitogenic and permeability-
enhancing activities are weak. PlGF is dispensable for embryonic development, but loss of 
PlGF impairs angiogenesis associated with tumors, inflammation and ischemia, and leads to 
prolonged healing of skin wounds (Carmeliet et al., 2001; Oura et al., 2003). In contrast to 
VEGF-A, PlGF seems to be downregulated by hypoxia (Gleadle et al., 1995). 
 
2.3.3 VEGF-B  
The biological role of VEGF-B (or VEGF related factor, VRF) is still largely unknown. 
VEGF-B is not required for normal vascular development of mouse embryos (Aase et al., 
2001; Carmeliet et al., 2001). In adults, it is expressed in heart and skeletal muscle, as well as 
in arterial wall, particularly in the pulmonary (lung) arteries (Li et al., 2001). The expression 
of VEGF-B is not regulated by hypoxia or cytokines (Enholm et al., 1997). Unlike other 
factors of the VEGF family, VEGF-B is O-glycosylated, which is rare among growth factors 
(Hudgins et al., 1992; Lu et al., 1995)  
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2.3.4 The subfamily of VEGF-C and VEGF-D 
VEGF-C (or VEGF related protein, VRP) and VEGF–D (or c-fos induced growth factor, 
FIGF)  form a  subfamily  of  VEGFs that  is  defined  by  long  amino-  (N-)  and  carboxy-  (C-)  
terminal extensions flanking the VHD (Achen et al., 1998). The VHDs of VEGF-C and 
VEGF-D  are  60%  identical  (Achen  et  al.,  1998).  The  cysteine  rich  C-terminal  domain  of  
both VEGF-C and VEGF-D resembles Balbiani ring 3 protein (Joukov et al. 1996), and is 
not present in any other known members of the VEGF family. The amino acid sequence of 
VEGF-D has three putative N-glycosylation sites of which two (residues 155-157 and 185-
187) are conserved with VEGF-C (Figure 6). 
 
VEGF-C and VEGF-D are expressed as preproproteins which are proteolytically cleaved 
into their mature forms, consisting only of the bioactive (receptor binding) VHD region. 
Stepwise proteolytic processing generates different forms of these proteins with increasing 
activity towards their receptors (Joukov et al., 1997, Stacker et al., 1999).  In general, VEGF 
family members exist as disulfide-bonded homodimers. However, the mature forms of 
VEGF-C and VEGF-D exist predominantly as non-covalent homodimers (Joukov et al., 
1997, Stacker et al., 1999). 
 
VEGF-C expression in embryos is localized in the mesenchyme surrounding the lymphatic 
vessels (Kukk et al., 1996) and it is essential for the development of lymphatic vessels 
(Kärkkäinen et al., 2004).  Both VEGF-C and VEGF-D were shown to induce lymphatic 
growth in vivo (Jeltsch et al., 1997; Veikkola et al., 2001) and induce proliferation and 
migration of lymphatic endothelial cells in vitro (Marconcini et al., 1999; Mäkinen et al., 
2001). They can also stimulate the proliferation and migration of blood vascular endothelial 
cells, increase vascular permeability and angiogenesis (Joukov et al., 1997, Mäkinen et al., 
2001; Witzenbichler et al., 1998).   
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Figure 6. The amino acid sequence of human VEGF-D aligned with other mammalian 
members of the VEGF family. Below the human VEGF-D sequence are the sequences of 
mouse VEGF-D (Orlandini et al., 1996), human VEGF-C (Lee et al., 1996), human 
VEGF165 (Tischer et al., 1991), human VEGF-B167 (Olofsson et al, 1996), and human 
PlGF-2 (Maglione, 1993), respectively. Residues that match the sequence of human VEGF-
D are boxed. The asterisks above the hVEGF-D sequence denote the eight cysteine residues 
that are conserved in all VEGF family members. Arrows denote positions of proteolytic 
cleavage that give rise to the major form of mature VEGF-C (Joukov et al., 1997). The N-
terminal cleavage sites for mature major and minor VEGF-D are marked with arrowheads 
(Stacker et al., 1999). The line above the hVEGF-D sequence denotes a putative signal 
sequence for protein secretion (von Heijne, 1986). Potential N-linked glycosylation sites in 
human VEGF-D are marked by brackets above the sequence. Solid circles above the 
hVEGF-D sequence denote cysteine residues involved in motifs that resemble those of silk-
like secretory Balbiani ring 3 protein (CX10CXCXC) (Joukov et al., 1996). Adapted from 
Achen et al., 1998. 
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2.3.5 VEGF-E 
The VEGF-Es were found as open reading frames in the genomes of three strains of the 
double-stranded Orf poxvirus (Lyttle et al., 1994; Ogawa et al., 1998). The virus induces 
proliferation of vascular endothelial cells and dilation of blood vessels in sheep, goats and 
sometimes  humans  (Lyttle  et  al.,  1994).  VEGF-E  family  members  are  the  only  known  
naturally occurring VEGF-related proteins that specifically bind to and activate only 
VEGFR-2 (Ogawa et al., 1998; Meyer at al., 1999). The angiogenic activity of VEGF-E is 
most likely similar to that of VEGF-A. 
 
2.3.6. svVEGF 
The most recently identified member of the VEGF family,  svVEGF (also called VEGF-Fs) 
was isolated from snake venom (hence sv) (Gasmi et al., 2000; Komori et al, 1999). svVEGF 
increases vascular permeability leading to hypotension and venom spread, thus contributing 
to Viperidae envenoming (Junqueira-de-Acevedo et al., 2004). It preferentially binds to and 
activates VEGFR-1, but also to some extent, VEGFR-2 (Takahashi et al., 2004).  
 
2.3.7 Glycosylation and Secretion  
Glycosylated proteins have carbohydrates covalently linked to their amino acid side chains. 
Carbohydrates can be linked either to the asparagine side chain by N-glycosidic bonds or to 
serine and threonine side chains by O-glycosidic bonds (Thomas and Segalof, 1994). All 
VEGFs are N-glycosylated to various extents except for VEGF-B which is O-glycosylated 
and its splice isoform, VEGF-B167 which is completely non-glycosylated. As most 
glycosylated proteins, VEGFs are secreted. The N-terminal region of all VEGFs contains a 
leader signal peptide for protein secretion (Von Heijne, 1986). 
 
2.3.8 Vascular endothelial growth factor receptors (VEGFRs) 
VEGF-receptors (VEGFRs); VEGFR-1 (or Fms-like tyrosine kinase-1, Flt-1), VEGFR-2 (or 
KDR in the human and Flk-1 in the mouse) and VEGFR-3 (or Flt-4) belong to the class III 
receptor tyrosine kinases. They all consist of seven immunoglobulin-homology domains, a 
transmembrane sequence and an intracellular portion containing a split kinase domain 
(Shibuya et al., 1990; Terman et al., 1991, Pajusola et al., 1994). The schematic structures of 
VEGFRs are shown in Figure 5. 
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VEGFRs are key regulators of the development and maintenance of the vertebrate vascular 
system. Their roles in vascularisation are partly overlapping, but independent. VEGFRs are 
expressed to different levels in vascular endothelial cells. They are all critical for embryonic 
vascular development as mutant mice deficient in each of these receptors die during 
embryogenesis due to profound abnormalities of the vascular system (Shalaby et al., 1995; 
Fong et al., 1995; Dumont et al., 1998). All three VEGFRs undergo alternative splicing (and 
possibly also proteolytic processing) to generate more than one form of these receptors. 
Naturally occurring truncated, soluble forms of VEGFR-1 and VEGFR-2 have been 
described (Kendall and Thomas 1993; Ebos et al., 2003). By trapping available growth 
factors, these soluble receptors act as competitive inhibitors. 
  
2.3.8.1 VEGFR-1   
VEGFR-1 binds VEGF-A, PlGF, VEGF-B and svVEGF. In addition to vascular endothelial 
cells, VEGFR-1 is also expressed on macrophages and it regulates the migration and gene 
expression of these cells (Sawano et al., 2001; Autiero et al., 2003; Shibuya, 2000). 
 
2.3.8.2 VEGFR-2  
VEGFR-2 is considered to be the major mediator of mitogenesis of endothelial cells and 
hence, angiogenesis.  VEGF-A, VEGF-E, svVEGF as well  as the mature forms of VEGF-C 
and VEGF-D bind to and activate VEGFR-2. Activation leads to stimulation of endothelial 
cell proliferation, migration and survival as well as blood vessel permeability. VEGFR-2 is 
highly expressed in vascular endothelial progenitors in early embryogenesis. During later 
stages of vascular development, VEGFR-2 expression declines, but is reactivated under 
pathological conditions such as tumorigenesis (reviewed in Matsumoto and Claesson-Welsh, 
2001).  
 
2.3.8.3 VEGFR-3  
A distinct structural feature of VEGFR-3 is the proteolytic cleavage within its fifth Ig-like 
loop. A disulfide bridge keeps the N-terminal part of the extracellular domain connected with 
the membrane anchored rest of the molecule (Pajusola et al., 1994). VEGFR-3 binds VEGF-
C and VEGF-D. During early vascular development, VEGFR-3 is expressed in developing 
blood vessels and it is required for normal vascular development. VEGFR-3 deficient mice 
die in utero around E10 due to defective remodelling and maturation of primary vascular 
network (Dumont et al., 1998). VEGFR-3 regulates the development and growth of 
 22
lymphatic vessels (Jeltsch et al., 1997; Mäkinen et al., 2001; Veikkola et al., 2001, 
Kärkkäinen et al., 2004) and after the formation of lymphatic vessels VEGFR-3 is detected 
almost exclusively on lymphatic endothelium (Dumont et al., 1998; Kaipainen et al., 1995). 
In adult tissues, VEGFR-3 expression occurs also in fenestrated endothelia (Partanen et al., 
2000), high endothelial venules and in the endothelia of angiogenic blood vessels in tumors 
(Partanen et al., 1999; Valtola et al., 1999). Furthermore, VEGFR-3 can also be upregulated 
on blood vessels during wound healing (Paavonen et al., 2000).  
 
2.3.9 Non-tyrosine kinase receptors 
In addition to VEGF-induced signalling through the VEGFRs, stimulation of endothelial 
cells is influenced by a number of non-tyrosine co-receptors such as heparin sulphate 
proteoglycans and neuropilins. Neuropilin-1 (NRP-1) and NRP-2 are known to be involved 
in axonal guidance of neurons, but they have also been identified as VEGF-binding proteins 
and part of the VEGF/VEGFR signalling complex (Soker et al., 1998). They are 
transmembrane non-tyrosine kinase receptors, expressed in endothelial cells (Herzog et al., 
2001; Kitsukawa et al., 1995; Soker et al., 1998). There is a preference for expression of 
NRP-1 on arterial endothelial cells and NRP-2 on venous and lymphatic endothelial cells 
(Herzog et al., 2001; Kärkkäinen et al., 2001). Neuropilins affect downstream signalling of 
VEGFRs; the question whether neuropilins on endothelial cells contribute to signalling 
independently of VEGFRs is not yet settled.  
 
Other potential co-receptors for the VEGFRs include integrins such as ???3 and ???1 
(reviewed in Stupack et al., 2004) and cell adhesion molecules such as vascular endothelial 
(VE)-cadherin (reviewed in Cavallaro et al., 2005).  
 
2.4 VEGF-D 
2.4.1 Discovery  
Human VEGF-D (hVEGF-D) was discovered soon after the mouse homologue, c-fos-
induced growth factor (FIGF, mVEGF-D) was reported in 1996 (Yamada et al., 1997; 
Orlandini et al., 1996). mVEGF-D was initially identified by using a differential screening 
strategy aimed at the identification of new c-fos responsive genes in mouse fibroblasts 
(Orlandini et al., 1996). Computer based homology search, using VEGF- and VEGF-C-
related sequences, was employed in the identification of hVEGF-D (Achen et al., 1998; 
Yamada et al., 1997). The human VEGF-D gene is located on the chromosome Xp22.31 
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(Yamada et al, 1997). The gene spans about 50 kb and is organized into six introns and seven 
exons. VEGF-D is highly conserved both at the nucleotide level (83% identity) and the 
amino acid level (84%) with respect to its murine homologue (Figure 6) (Rocchigiani et al., 
1997).  
 
2.4.2 Expression 
In cultured fibroblasts VEGF-D regulation differs from VEGF-C. VEGF-D is induced in 
vitro by c-fos while VEGF-C induction is c-fos independent (Ristimäki et al., 1998). This 
suggests that VEGF-D is a downstream effector of c-fos in development and/or tumor 
progression. The c-fos protooncogene plays a central role in the nuclear response to 
stimulatory signals that regulate cellular proliferation and differentiation. The gene codes for 
a transcription factor that belongs to AP-1 family (Ransone and Verma 1990; reviewed in 
Angel and Karin, 1991). 
 
In human tissues, VEGF-D is expressed mostly in lung and heart. Expression has also been 
detected from skeletal muscle, small intestine, fetal lung, colon and pacreas (Yamada et al., 
1997; Rocchigiani et al., 1997; Achen et al., 1998). Upregulation of VEGF-D expression has 
also been detected in human tumors (Achen et al., 2001; Partanen et al., 2000). In mouse 
embryos VEGF-D is expressed in several organs, including limb buds, teeth, heart, and 
pituitary  as  well  as  lung  and  kidney  mesenchyme,  liver,  derma,  and  periosteum  of  the  
vertebral column (Avantaggiato et al., 1998; Kukk et al., 1996). VEGF-D is also expressed 
by macrophages (Schoppmann et al., 2002). In contrast to other VEGFs, VEGF-D is not 
induced by hypoxia or by serum factors. In fact, VEGF-D is induced by direct cell-cell 
contact mediated by the surface molecule cadherin-11 (Orlandini and Oliviero, 2001). 
Furthermore, VEGF-D is highly expressed in fibroblasts grown under low serum 
concentrations (Orlandini et al., 1996). ?-catenin, a transcription factor that stimulates cell 
proliferation, is a negative regulator of the expression of both human and mouse VEGF-D. 
This regulation is indirect and occurs at the level of VEGF-D mRNA stability (Orlandini et 
al., 2003). 
 
The expression of VEGF-D has been reported in many cancer types (Table 1). The 
mechanism regulating VEGF-D expression in tumors is not fully understood. It has been 
suggested that VEGF-D is expressed during differentiation, but not actively proliferating 
cells, because it is negatively regulated by ?-catenin (Orlandini et al., 2003).  
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2.4.3 Modification, Processing, Glycosylation 
The expression of structurally distinct protein isoforms is a common mechanism in 
eukaryotes to generate proteins with related yet distinct structures, regulation and function. 
As mentioned earlier, VEGF-C and VEGF-D are synthetized as precursor proteins. In vitro 
studies in 293EBNA cells show that VEGF-D is secreted as a prepropeptide of ~53 kDa, 
which is rapidly secreted from the cells (Stacker et al., 1999). During or after secretion, this 
prepropeptide can be proteolytically cleaved at the N- and C-termini (Figure 7). Due to 
proteolytic processing, VEGF-D exists in numerous forms in the extracellular milieu. Some 
VEGF-D molecules are fully processed (only VHD left), whereas others are partially 
processed (VHD and N/C-terminal domain) or remain unprocessed (Stacker et al., 1999). 
Fully processed forms with a molecular weight ~20 kDa are referred to as mature VEGF-Ds.  
 
 
Figure 7.   Schematic representation of VEGF-D processing by 293EBNA cells. Two forms of 
unprocessed VEGF-D are secreted from the cell: a monomer (left side) and a disulfide-linked 
dimer (right side). Arrows lead from the intracellular forms to the products of stepwise proteolytic 
processing, which give rise to a mature form that is predominantly a non-covalent dimer of the 
VHD. However, not all polypeptides become fully processed; therefore, unprocessed and partially 
processed forms are detected in cell culture supernatants. N-pro denotes the N-terminal 
propeptide; C-pro, the C-terminal propeptide; VHD, the VEGF homology domain; dotted lines, 
non-covalent interactions between domains; -S-S-, intersubunit disulfide bridges; N-,  the  N  
termini of polypeptides; arrowheads, the approximate locations of proteolytic cleavage sites. 
Adapted from Stacker et al., 1999. 
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Two distinct N-terminal cleavage sites were identified that differ from those of VEGF-C. In 
this work, the proteins resulting from differential N-terminal cleavage, will be referred to as 
major (amino acids 89-205) and minor (amino acids 100-205) according to Stacker et al., 
1999. A unique C-terminal cleavage site was identified at the homologous position as that 
for VEGF-C (processing sites are indicated in Figure 6). Processing might occur also in vivo, 
for example in mouse embryonic lung (Stacker et al., 1999). The serine protease plasmin has 
been shown to cleave both N- and C-terminal propeptides from the VHD of human VEGF-D 
(McColl et al., 2003). 
 
Alternative splicing of mouse VEGF-D mRNA produces two different protein isoforms, 
VEGF-D358 and VEGF-D326, with distinct C-termini. Both isoforms are proteolytically 
processed in a similar fashion to human VEGF-D to generate a range of secreted derivatives. 
However, these isoforms are differentially glycosylated when produced in vitro (Baldwin et 
al., 20012). Hence, RNA splicing, protein glycosylation and proteolytic prosessing are 
mechanisms for generating structural diversity of mouse VEGF-D. Alternative splicing of 
human VEGF-D has not been reported.  
 
Unlike the other members of the VEGF family, VEGF-C and VEGF-D contain two potential 
glycosylation sites in the mature protein. Secreted VEGF-D has been reported to be 
glycosylated at asparagine-160 residue. Removal of this glycosylation by substituting 
asparagine with proline reduced angiogenic activity of VEGF-D (Marconcini et al., 1999). 
 
Determining the function of both N- and C-terminal propeptides of VEGF-D requires further 
studies. It is possible that differences in the amino acid sequence and glycosylation of the C-
terminal propeptide could affect protein localization by influencing interactions with 
extracellular matrix components as well as protein stability and function. Such variation 
could also be tissue- or organ-specific (Baldwin et al., 20012). 
 
2.4.4 Binding 
Proteolysis is important for receptor binding as fully processed (mature) human VEGF-D 
binds both VEGFR-2 and VEGFR-3 with much greater affinity than does the unprocessed 
form (Stacker et al., 2001). Studies of receptor-binding specificity of the mature form of 
mouse VEGF-D revealed an unexpected difference from its human homologue: the mature 
protein did not bind to mouse VEGFR-2 (Baldwin et al., 20011). Such difference has not 
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been  shown  for  VEGF-C.  In  addition,  mVEGF-D  was  able  to  bind  human  VEGFR-2  and  
hVEGF-D  bound  to  mouse  VEGFR-2,  indicating  that  both  the  receptor  and  the  ligand  
contribute to the inability of mouse VEGF-D/VEGFR-2-signalling (Baldwin et al., 20011).  
This complicates the use of mouse models because this different binding pattern might 
reflect a different function.  
 
2.4.5 Function 
Mature hVEGF-D binds with high affinity to VEGFR-2 and VEGFR-3 but the consequences 
of this binding and the signalling pathways involved are far from clear. Many reports have 
shown the strong angiogenic or lymphangiogenic properties of VEGF-D. However, little is 
known of the physiological role of VEGF-D. VEGFR-3 is thought to be primarily 
responsible for mediating the effects of VEGF-D in lymphatic endothelial cells, and 
VEGFR-2 for mediating the effects in blood vascular endothelial cells.  
 
mVEGF-D is a potent angiogenic factor in rabbit cornea, in vivo in a dose-dependent manner 
(Marconcini et al., 1999). This suggests that mVEGF-D could activate rabbit VEGFR-2, 
although it is not known if this ligand binds VEGFR-2 in rabbit. In addition, mVEGF-D 
stimulates morphological, mitogenic and motogenic responses in vitro in HUVECs (human 
umbilical cord vein endothelial cells) and in an immortal cell line derived from Kaposi’s 
sarcoma lesions (Marconcini et al, 1999). Adenoviral delivery of VEGF-D in adult tissues 
induces tissue-specific angiogenesis and lymphangiogenesis (Byzova et al., 2002). This 
suggests that the biological effect of VEGF-D is dependent on the abundance of blood and 
lymphatic vessels expressing its receptors in a given tissues.   
 
When comparing the actions of VEGF-D to VEGF-A, a better known ligand of VEGFR-2, 
VEGF-D was found to induce VEGFR-2 tyrosine phosphorylation, which eventually leads to 
multiple biological responses including cell survival, migration, tubulogenesis and in vivo 
angiogenesis. In most cases the effects of VEGF-D were less effective and slower than those 
of  VEGF-A.  However,  occasionally  the  effect  of  VEGF-D was  better  sustained  (Jia  et  al.,  
2004).  
 
Little is known of the characteristic features of lymphatic endothelial cells (LECs). Isolated 
LECs have been available for molecular studies only for a few years (Kriehuber et al., 2001). 
Thus the biochemical signalling pathways activated via VEGFR-3 are poorly characterized. 
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VEGFR-3 stimulation alone (by mutant VEGF-C) protects the lymphatic endothelial cells 
from serum deprivation-induced apoptosis and induces their growth and migration (Mäkinen 
et al., 2001).  
 
2.4.6 Animal models of VEGF-D 
VEGF-D deficient mice did not have a profound phenotype. They were healthy and fertile, 
had a normal body mass and displayed no pathologic changes consistent with a defect in 
lymphatic function. The only feature of VEGF-D deficient mice was the slightly reduced 
abundance of the lymphatics adjacent to bronchioles (Baldwin et al., 2005). This suggests 
that VEGF-D does not play a major role in lymphatic development or that VEGF-C or 
another, still unknown activating VEGFR-3 ligand can compensate for VEGF-D during 
development. However, no VEGF-C upregulation was detected in VEGF-D deficient mice, 
suggesting that if such compensation occurs, then it does so without a requirement for 
significantly elevated levels of VEGF-C expression (Baldwin et al., 2005). 
 
In  order  to  analyse  the  effects  of  VEGF-D in vivo, transgenic mice overexpressing human 
VEGF-D in epidermal keratinocytes under the keratin 14 (K14) promoter, were created. 
K14-VEGF-D mice appeared healthy and their growth and reproductive rates were normal. 
K14-VEGF-D induced the growth of lymphatic vessels in the skin, whereas the blood vessel 
architecture was not affected. The extensive lymphatic growth appeared to result from both 
increased endothelial cell proliferation in the existing lymphatic vessels and from the 
formation of additional lymphatic vessels (Veikkola et al., 2001).  
 
2.4.7 VEGF-D in cancer 
VEGF-D can induce tumor angiogenesis through VEGFR-2 and tumor lymphangiogenesis 
through VEGFR-3. It has been shown to promote the metastatic spread of tumor cells via the 
lymphatics (Stacker et al., 2001). Expression of VEGF-D in a mouse tumor model stimulated 
lymphangiogenesis in solid tumors; this process promoted the metastatic spread of tumor 
cells via the lymphatics, and could be blocked by a neutralizing VEGF-D antibody (Achen et 
al., 2000; Achen et al., 2001; Stacker et al., 2001). Several reports have shown the 
involvement of VEGF-D in different types of cancers in animal models and human cancers 
(Table 1).  
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Table 1. Involvement of VEGF-D  in Cancer (adapted and modified from Achen and 
Stacker, 2006).  
Animal models showing 
VEGF-D is 
lymphangiogenic* 
Animal models showing 
VEGF-D promotes lymph 
node metastasis* 
Human cancers in which 
VEGF-D correlates with 
lymph node metastasis 
Transgenic mouse skin[1] 293EBNA xenograft[4] Endometrial carcinoma[7] 
   
Adenoviral delivery to 
skin[2] 
MiaPaCa-2 pancreatic 
xenograft[5] 
Epithelial ovarian 
carcinoma[8] 
   
Adenoviral delivery to 
muscle[3] 
Capan-1 pancreatic 
xenograft[5] 
Breast carcinoma[9]** 
   
 TKB5 lung cancer 
xenograft[6] 
 
* Indicates the distinct biological model systems in which the effects have been 
demonstrated. **Although reported in the cited reference, this correlation of growth factor 
expression with lymph node metastasis was not found in at least one study. Table references 
[1] Veikkola et al., 2001; [2] Byzova et al., 2002; [3] Rissanen et al., 2003; [4] Stacker et al., 
2001; [5] Von Marschall et al., 2005; [6] Ishii et al., 2004; [7] Yokoyama et al., 20031; [8] 
Yokoyama et al., 20032, [9] Nakamura et al., 2003. 
 
2.4.8 Future applications of VEGF-D  
Growth factors may be potential targets for therapeutic approaches designed to restrict 
metastasis by blocking tumor angiogenesis and lymphangiogenesis. Most primary tumors are 
removed surgically. Antimetastatic treatment after operation could be useful for restricting 
the spread of tumor cells from remnants of primary tumors not removed during surgery. 
Anti-(lymph)angiogenic therapy could also provide a more promising prognosis in cases of 
inoperable primary tumors and preexisting cancer metastases. In addition to therapeutic 
possibilities, growth factors could have prognostic value; VEGF-D expression has been 
reported as an independent prognostic factor in predicting relapse-free survival and overall 
survival in gastric carcinoma (Shida et al., 2005). The first anti-angiogenic drug approved for 
clinical therapy was a humanized monoclonal antibody (Avastin) against angiogenesis 
inducer vascular endothelial growth factor (VEGF); it has improved the survival rates of 
patients of colorectal cancer in combination with chemotherapy (reviewed in Kerr, 2004).  
 
2.5. Recombinant protein production in Drosophila Schneider 2 (S2) cells 
Recombinant expression of mammalian proteins in insect cells offers significant advantages 
when compared to mammalian cell expression systems: expression levels are usually higher 
and scaling-up and overall culture procedures are faster and easier. Yet many of the post-
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translational modification pathways present in mammalian systems are also utilized in insect 
cells, allowing the production of recombinant proteins functionally similar to native 
mammalian proteins (Johansen et al., 1989). Active, glycosylated cytokines, such as human 
interleukin 5 (Johanson et al., 1995) and human interleukin 12 (Lehr et al., 2000) have been 
successfully produced in the Drosophila melanogaster Schneider line 2 (S2), which is 
derived from a primary culture of embryos 20 to 24-hours old (Schneider, 1972).   
 
The Drosophila Ac5 promoter allows high-level, constitutive expression of recombinant 
proteins in Drosophila S2 cells. It is derived from the major cytoskeletal actin gene of 
Drosophila melanogaster,  the  actin  5C  gene.  Actually,  the  Ac5  promoter  consists  of  two  
promoters, the proximal and the distal one, which control the synthesis of actin in a tissue- 
and developmental stage-specific manner (Chung and Keller, 1990). This very strong 
promoter has widely been used for expression of heterologous genes in cultured cells.  
 
Frequently, secretion of recombinant proteins into the culture medium improves yield, 
quality and facilitates purification. Drosophila BiP signal sequence is derived from a protein 
called HSC3, a Drosophila melanogaster homologue for of the vertebrate immunoglobulin 
binding chaperone protein (BiP) (Rubin et al., 1993). This hydrophobic secretion signal 
efficiently targets recombinant proteins into the secretory pathway of S2 cells. 
  
2.6. Protein purification  
With chromatographic methods, it is possible to separate molecules according to their 
chemical and physical characteristics such as charge, hydrophobicity, affinity, solubility and 
molecular weight. Liquid chromatography provides the separation power needed to purify 
even subtle molecular variants from complex mixtures, combined with gentle chemical and 
physical conditions which enable the recovery of biological activity for complex 
macromolecules. Chromatography is highly scaleable and can be used for many applications. 
In high performance liquid chromatography (HPLC) media, the particle diameter has been 
reduced compared to the first-generation packings, resulting in faster separations and a better 
resolution.  
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3. AIMS OF THE STUDY 
Although there have been many reports showing the angiogenic and lymphangiogenic effects 
of VEGF-D, its physiological role is still largely unknown. Despite its close relationship to 
VEGF-C, it seems not to be a prerequisite for lymphangiogenesis as knocking out its gene in 
mice does not result in any obvious phenotype. Closer examination of all reports of VEGF-D 
function shows that most of these studies are severely hampered by incomplete 
characterization of the specific form of VEGF-D that was used (Table 2). VEGF-D is 
proteolytically processed during or after secretion, resulting in different forms of mature 
protein (Figure 8). Proteolytic modification of other growth factors such as PDGF-A 
(Siegfried et al., 2003) and FGF-1 (Grieb and Burgess, 2000) has a fundamental impact on 
the biological activity of these proteins. VEGF-D is no exception, processing significantly 
increases its activity towards VEGFR-2 and VEGFR-3 (Stacker, 1999). The fact that the 
closely related human VEGF-D and mouse VEGF-D have different receptor binding patterns 
(Baldwin et al., 20011) indicates the impact of small modifications to biological activity. 
Surprisingly, it is still unknown whether the differential N-terminal cleavage of VEGF-D has 
any effect on receptor binding activity or on receptor activation.  
 
 
 
Figure 8.   Schematic representation of VEGF-D. The VEGF-D domain structure is at the 
top. SS denotes the signal sequence for protein secretion, N-terminal pro and C-terminal pro 
denote the propeptides, and VHD the VEGF homology domain. Beneath are shown the 
proteolytic cleavage sites in VEGF-D marked by arrows. Potential N-linked glycosylation 
sites are marked with asterisks. Adapted from Stacker et al., 1999.  
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Table 2. VEGF-D expression constructs used in previous experiments. h- human, m– 
murine, FL– full length, numbers denote amino acids that are included in the protein (see 
Figure 6),  N– aminoterminal, C– carboxyterminal, H6– Histidine tag, FLAG– FLAG tag, 
met- methionine 
Function  Form Promoter Signal 
peptide 
Expressed 
in 
Reference 
Largely unknown hVEGF-Dminor h100-201 Native native 
many 
tissues 
Stacker et 
al., 1999 
Largely unknown hVEGF-Dmajor h89-201 Native native 
many 
tissues 
 Stacker et 
al., 1999 
Induction of 
neovascularization in 
rabbit corneas 
(implantation of VEGF-
D expressing CHO-
cells) 
m1-208-CFLAG CMV native CHO-cells Marconcini et al, 1999 
Induction of 
neovascularization in 
rabbit corneas 
(implantation of pellets 
with purified VEGF-D) 
m91-208-NH6 CYC1 
Kluyveromyces 
lactis toxin 
leader peptide 
yeast Marconcini et al, 1999 
Induction of in vitro 
angiogenesis and 
proliferation of HUVECs 
m91-208-NH6 CYC1 
Kluyveromyces 
lactis toxin 
leader peptide 
yeast Marconcini et al, 1999 
Stimulation of  
proliferation and 
migration of KS-IMM 
cells 
m91-208-NH6 CYC1 
Kluyveromyces 
lactis toxin 
leader peptide 
yeast Marconcini et al, 1999 
Mitogenic for bovine 
aortic endothelial cells 
h93-201-NFLAG 
aka VEGF-D???C ? IL-3 COS-cells 
Achen et al, 
1998 
3H-thymidine 
incorporation in human 
microvascular 
endothelial cells ? 
h93-201-NmetCH6 
(rhVEGF-D from 
R&D Systems?) 
? CD33 Sf 21-cells 
Marconcini  
according to 
R&D 
Systems, 
publication 
not found! 
Preferred induction of 
lymphangiogenesis to 
angiogenesis in rabbit 
Ad hFL CMV native   Rissanen et al, 2003 
Induction of 
arteriogenesis and 
vascular permeability as 
well as 
lymphangiogenesis in 
rabbit 
Ad-hVEGF-D???C CMV ?   Rissanen et al, 2003 
Stimulation of mitogenic 
activity and  
morphological 
alterations in mouse 
fibroblasts 
mFL CMV native COS-/ Orlandini et al, 1996 
Stimulation of tissue-
specific angiogenesis 
and lymphangiogenesis 
in rat 
Ad-hVEGF-D???C CMV ? 293 cells Byzova et al, 2002 
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Studying the true physiological role of VEGF-D requires significant amounts of high quality 
protein comparable in its biological activity to natively occurring forms. Commercially 
available VEGF-D protein does not correspond to any natively occurring form and it is 
largely biologically inactive towards VEGFR-3 (Mäkinen et al., 2001). The use of various 
forms of VEGF-Ds in different studies presents a serious problem when these studies should 
be compared with each other. The goal of this study is to produce and purify high quality 
biologically active VEGF-D.  
 
In more detail, the study includes: 
1. Cloning of various hVEGF-D forms into two expression vectors.  
2. Expression of hVEGF-D in Drosophila S2 cells.  
3. Purification of hVEGF-D.    
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4. MATERIALS AND METHODS  
4.1 Materials 
Materials and their suppliers are listed in Table 3. Table 4 shows the buffer compositions 
used in the experiments later described.  
  
             Table 3. Materials and suppliers. 
Name Supplier 
BCA Protein assay   Pierce 
Biorad Protein assay   Biorad 
Bovine serum albumin (BSA) MP Biomedicals Inc. 
Calf Intestinal Phosphatase (CIP) Finnzymes 
Chymotrypsinogen Calbiochem 
Coomassie stain solution Biorad 
DEAE Sepharose CL-6B  GE Healthcare (GEH) 
DNA Polymerase I, Large fragment (Klenow) New England Biolabs 
dNTP mix Finnzymes 
Drophila Schneider 2 (S2) insect cells  Invitrogen 
Dynazyme II DNA polymerase  Finnzymes 
Effectene transfection reagent  Qiagen 
Generuler 100bp and 1kb DNA ladders Fermentas 
High-Range Rainbow Molecular Weight 
Marker 
GEH 
HiTrap DEAE Sepharose Fast Flow 1 ml 
column  
GEH 
HiTrap SP Sepharose Fast Flow 1 ml column  GEH 
HRP-conjugated Rabbit anti-goat antibody Dako 
HRP-conjugated Rabbit anti-mouse antibody Dako 
Hygromycin B  Calbiochem 
HyQ SFX-Insect cell culture medium  HyClone 
Interleukine-3 (IL-3) Calbiochem 
Murine anti-His5–IgG Qiagen 
Ni-NTA Superflow Sepharose FF Qiagen 
One Shot INV110 Competent Cells Invitrogen 
Ovalbumin Calbiochem 
pAc5-HygroSapI  (Invitrogen/Michael Jeltsch) 
pAc5SapI   (Invitrogen/Michael Jeltsch) 
pCoHygro Invitrogen 
Plasmid Maxiprep Kit Qiagen 
Plasmid Miniprep Kit Qiagen 
Polyclonal Goat ?-mVEGF-D Ab  R&D Systems 
Primers Oligomer Oy  
Protein A sepharose (PAS)  GEH 
Protein standard: Low molecular weight 
(LMW)-SDS Marker Kit 
GEH 
Protran BA83 nitrocellulose membrane  Whatman Schleicher & Schuell BioScience 
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QIAEXII Gel Extraction Kit  Qiagen 
Qiaquick PCR Purification Kit  Qiagen 
Rapid Ligation Kit  Roche 
Recombinant human VEGF-C Kärpänen et al., 2006 
Restriction enzymes New England Biolabs 
Ribonuclease A   Calbiochem 
Superdex 75 10/300 GL column GEH 
VEGFR3-IgG Mäkinen et al., 2001  
All other chemicals Sigma Aldrich 
 
 
 
 Table 4. All the buffers used in experiments. 
Buffer  Composition 
Binding buffer (BB) 0,5% BSA, 0,02% Tween 20-PBS 
Bjernum & Schafer-Nielsen transfer buffer  48 mM Tris, 39 mM glycine, 20% MetOH 
CIEX universal buffer  30 mM Na2HPO4, 30 mM Na formate, 60 mM Na acetate 
Lysis buffer  20% SDS, 40% dimethylformamide, 2% glacial acetic acid pH 4.7 
PBS (Phosphate-buffered saline) 154 mM Sodium Chloride, 10 mM phosphate pH 7.4 
TBS (Tris-buffered saline) 154 mM NaCl, 10 mM Tris pH 7.4  
TBS High salt 500 mM NaCl, 10 mM Tris pH 7.4 
 
 
 
 
4.2 Expression constructs 
Six different hVEGF-D constructs were prepared. These constructs differ in the exact 
location  of  the  N-  and  C-terminus  and  the  affinity  tag  (if  used).  Names  and  structures  of  
these constructs are presented in Figure 9. Constructs were inserted in two different 
expression vectors, the one including and the other lacking the selection marker. Similar 
constructs were also made for VEGF-A and VEGF-C, these were used as negative and 
positive controls, respectively. Maps of all vectors and constructs can be found from 
Appendix I.  
 
 35
 
Figure 9. Names and structures of the recombinant hVEGF-D constructs.  
 
 
4.2.1 Cloning procedures 
VEGF-A, -C and -D constructs were created by polymerase chain reaction (PCR). 500 ng of 
pFB1-melSP-hVEGF-A165-H6 (Michael Jeltsch, personal maxi prep #418) and 400 ng 
pFB1-dNdC-C1His-melSP-hVEGF-C (Michael Jeltsch, personal maxi prep #54), were used 
as templates for controls. 200 ng of human VEGF-D cDNA (Achen et al, 1998) in pBSKII-
vector (pBSKII(+)-hVEGF-D-FL, Michael Jeltsch, personal maxi prep #142) was used as a 
template for VEGF-D constructs. Primer sequences are listed in Table 5. The PCR was 
performed using Dynazyme II DNA polymerase according to manufacturer’s instructions in 
a final volume of 100 µl.  
 
 
 
 
Ac5-promoter 
FAAT… …SIIRR 
dNdC-hVEGF-Dmajor-untagged BiP 
Ac5-promoter 
BiP 
FAAT… …SIIRR 
dNdC-hVEGF-Dmajor-SIIRRH6 His6 
Ac5-promoter 
BiP 
FAAT… …SII 
dNdC-hVEGF-Dmajor-SIIH8 His8 
Ac5-promoter 
BiP 
KVID… …SIIRR 
dNdC-hVEGF-Dminor-SIIRRH6 His6 
Ac5-promoter 
KVID… …SIIRR 
dNdC-hVEGF-Dminor-untagged BiP 
Ac5-promoter 
BiP 
KVID… …SII 
dNdC-hVEGF-Dminor-SIIH8 His8 
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Table 5.  Primer names and sequences 
Primer name Sequence  Laboratory 
internal 
number 
Used for 
Major Forward        5’-GATCTGAGCT CTTCGCGGGT 
TTGCAACTTT CTATGAACAT  
TG-3’   
V10  VEGF-D Insert 
PCR 
Minor Forward        5’-GATCTGAGCT CTTCGCGGGA 
AAGTTATAGA TGAAGAATGG 
CAAAG-3’  
V158  VEGF-D Insert 
PCR 
Untagged 
Reverse   
5’-TGCATCTAGA TCATCTTCTG 
ATAATTGAGT AAGGATGG-3’ 
15340 VEGF-D Insert 
PCR 
His8-tagged 
Reverse 
5’-CATCTAGATC AATGATGGTG 
ATGATGATGG GATGGATAAT 
TTGAGTAAGG ATGGCGG-3’  
V181  VEGF-D Insert 
PCR 
His6-tagged 
Reverse 
5’-CATCTAGATC AATGATGATG 
ATGGTGGTGT CTTCTGATAA 
TTGAGTAAGG ATGG-3’  
V182 VEGF-D Insert 
PCR 
VEGF-A165 Fwd 5’-GATCTGAGCT CTTCGCGGGG 
CACCCATGGC AGAAGGAG-3’ 
V8 VEGF-A Insert 
PCR 
VEGF-C Fwd 5’-GATCTGAGCT CTTCGCGGGA 
CAGAAGAGAC TATAAAATT T 
GCTGC-3’ 
V9 VEGF-C Insert 
PCR 
VEGF-A/C Rev 
5’-GGAGGTTTTT TAAAGCAAGT-3’ 
61192 VEGF-A/C Insert 
PCR 
Ac Forward 5’-ACACAAAGCC GCTCCATCAG-
3’ 
18939 sequencing both 
vectors 
Ac Reverse 5’-GTGGTTTGTC CAAACTCATC 
AA-3’ 
V34 sequencing pAc5-
Sap 
Copia Reverse 5’-CATATCAAAT ATAAAGTAGT 
GTTG-3’ 
19014 sequencing 
pAc5Hygro-Sap 
 
 
PCR program: Initial denaturation 90 sec, 94ºC 
  Denaturation  30 sec, 94ºC 
  Annealing   30 sec, 57ºC 
  Elongation  30 sec, 72ºC 
  Final elongation 7 min, 72ºC 
  22 cycles 
 
The PCR products were purified with a Qiaquick PCR purification kit according to the 
instructions of the manufacturer. Purified VEGF-D inserts were digested with XbaI and 
blunted with DNA polymerase I, large (Klenow) fragment. The Klenow enzyme was used at 
a  concentration  of  1  U/µg DNA and the  final  concentration  of  dNTP mixture  was  50  µM.  
The reaction mixture was incubated for 20 min at RT and inactivated for 20 min at 75ºC. 
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Thereafter  the  fragments  were  digested  with  SapI.  VEGF-A  and  VEGF-C  inserts  were  
digested with SapI and ScaI.  
 
The vectors pAc5SapI and pAc5-HygroSapI were opened with SapI/StuI and SapI/PmeI, 
respectively, and dephosphorylated using calf intestinal phophatase (CIP) for 1 h at 37ºC. 
Inserts and vectors were electrophoretically separated in agarose gels. Fragments were 
visualized under UV light after staining with EtBr. The correct fragments were identified by 
comparing to DNA standards (Generuler 100 bp and 1 kb DNA ladders), excised from gel 
and purified with QIAEX II Gel Extraction Kit according to instructions of the supplier. All 
six different VEGF-D inserts (about 460 basepairs in size) were ligated to both pAc5SapI 
and pAc5-HygroSapI vectors using a Rapid Ligation Kit. 2.5 µl of each ligation reaction mix 
was added to 25 µl of One Shot INV110 Competent Cells and the transformation was carried 
out according to instructions of the supplier. 150 µl of each transformation reaction was 
plated on Luria-agar plates containing 100 ?g/ml ampicillin. Plates were incubated o/n at 
37ºC. Clones were picked, cultured and plasmids were isolated using a Plasmid Miniprep 
Kit. The presence and the sequence of the correct insert were confirmed by restriction 
analysis  of  the  minipreps  and  by  DNA  sequencing  of  the  insert  after  preparation  of  a  
maxiprep (Plasmid Maxiprep Kit). The primers that were used to sequence constructs are 
listed in Table 5. Sequencing was performed with ABI 3130xl Genetic Analyzer (Applied 
Biosystems). 
 
4.3 Expression of recombinant human VEGF-D in insect cells 
Drophila Shneider 2 (S2) insect cells grown with HyQ SFX-Insect cell culture medium 
without serum at 27ºC, were plated on 12 well-plates 24h prior to transfection at a density of 
120 000 cells/well. Transfections were performed in duplicates with Effectene transfection 
reagent, following the manufacturer’s protocol.  Constructs without hygromycin resistance 
gene were cotransfected with the selection vector pCoHygro at a 20:1 ratio. Hence all 
transfectants contained the E. coli hygromycin resistance gene (Gritz and Davies, 1983) for 
selection with the antibiotic hygromycin B. The expression levels and VEGF-D activities 
were tested from transient transfection supernatants, harvested 3 days after transfection. 
Selection was started after harvesting transient transfection supernatants by adding 
hygromycin B to the medium at a final concentration of 0.5 mg/ml. The cell culture media 
was changed every 3 or 4 days for five weeks. Selection antibiotics were also later included 
in the cell culture to avoid plasmid loss.  
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4.4 Testing the expression of VEGF-D 
Prior to all experiments the harvested medium was centrifuged on a table top centrifuge at 
100 g for 8 min (henceforth called cell supernatant (sup) or starting material) and for 
purification procedures it was also sterilized by filtering through a 22 ?m filter (Millipore). 
VEGF-D expression level was detected by Western blot analysis of immunoprecipitated and 
electrophoresed cell supernatants.  
Immunoprecipitation. Cell supernatants were immunopreciptated, as described in Table 6. 
Protein A sepharose (PAS) in PBS (50 ?l of 50% slurry) was added to each sample and the 
tubes were slowly rotated o/n at 4ºC.  
 
Table 6.  Immunoprecipitation. (BB- binding buffer)  
Construct Antibody Additives 50% PAS 
Untagged, 500?l 500ng/ml Goat ?-mVEGF-D Ab   50?l 
Untagged, 500?l 250ng/ml VEGFR3-IgG 25?l 20xBB 50?l 
His-tagged, 500?l 600ng/ml Murine ?-His5–IgG   50?l 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Immunoprecipitates were centrifuged at 550 g for 3 min and 20 ?l 2x Laemmli standard 
buffer (Laemmli, 1970) was added. Samples including the Low Molecular Weight Marker 
(LMW) standard were then boiled for 5 minutes at 95ºC and separated in SDS-PAGE of 6% 
stacking gel and 17% separation gel under reducing conditions (Laemmli, 1970).   
 
Western blot. Proteins were blotted to Protran BA83 nitrocellulose membrane on a Trans-
Blot SD Semi-Dry Transfer Cell-apparatus (Biorad). Prior to blotting, the membrane and the 
gels were equilibrated for 15 min in Bjernum & Schafer-Nielsen transfer buffer. Proteins 
were transferred to the membrane in transfer buffer using 15 V (5.5 mA/cm2). After blotting, 
the  membrane  was  Ponceau-stained  (Hassan  et  al,  1987)  for  5  min  and  the  standards  were  
marked on the membrane with a pencil. Membranes were washed and incubated on a turning 
table according to Table 7. Proteins were visualized on X-ray film by a standard ECL 
method (Schneppenheim and Rautenberg 1987; Harper and Murphy 1991; Schneppenheim et 
al., 1991). 
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Table 7. Incubations and washes of Western blot. RT- room temperature 
  
dNdC-hVEGF-
Dmajor_untagged 
dNdC-hVEGF-
Dmajor_SIIRR-H6 Time and temp. 
1 TBS TBS 10 min, RT 
2 TBS TBS 10 min, RT 
3 3%BSA-TBS (blocking solution) 
3%BSA-TBS 90 min, RT 
4   TBS-0,1%Tween, high salt 10 min, RT 
5   TBS-0,1%Tween, high salt 10 min, RT 
6   TBS 10 min, RT 
7 
  
Goat ?-mVEGF-D Ab 
1:250 in blocking 
solution 
Murine ?-His5–IgG 
1:1000 in blocking solution 
o/n, 4°C  
  
8 TBS-0,05%Tween TBS-0,1%Tween, high salt 10 min, RT 
9 TBS-0,05%Tween TBS-0,1%Tween, high salt 10 min, RT 
10 TBS TBS 10 min, RT 
11 
  
HRP-conjugated Rabbit 
anti-goat antibody 
1:2000 in 10% (w/v) 
milk powder-TBS 
HRP-conjugated Rabbit 
anti-mouse antibody 
1:1000 in 10% (w/v) milk 
powder-TBS 
Untagged 120min, 
RT 
SIIRR-H6 60min, 
RT 
12 TBS-0,1%Tween TBS-0,1%Tween, high salt 10 min, RT 
13 TBS-0,1%Tween TBS-0,1%Tween, high salt 10 min, RT 
14 TBS-0,1%Tween TBS-0,1%Tween, high salt 10 min, RT 
15 TBS-0,05%Tween TBS-0,1%Tween, high salt 10 min, RT 
16   TBS 10 min, RT 
 
 
4.5 Protein analysis 
Protein amounts and activities were measured after every purification step starting from cell 
supernatants to the final product. Western blotting, silver staining and Coomassie staining 
(Sambrook et al. 1989) of SDS-PAGEs were used to identify the peak fractions of produced 
and purified rhVEGF-Ds.  
 
4.5.1 Protein concentration 
The total protein concentrations of purification intermediates and products were determined 
using either Biorad Protein assay or BCA Protein assay. Standard curves were constructed 
using bovine serum albumin (BSA) in the corresponding sample buffer. Standard curves 
were prepared covering the range of 0-5 ?g/?l in the Biorad assay and 0-30 ?g/?l in the BCA 
assay. Protein concentrations of samples were calculated based on the linear part of the 
regression curve based on the standards (Figure 10).  
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Figure 10. Standard curves from BCA-assay for each purification step. A standard curve 
was prepared separately for each sample buffer. The sample for which each curve was 
constructed for is indicated in the parentheses. AIEX- anion exhange chromatography, SEC- 
size exclusion chromatography, sup- cell supernatant (starting material). 
 
 
4.5.2 MTT-Ba/F3-bioassays 
The capacity of produced recombinant hVEGF-D to bind to its receptors VEGFR-2 and 
VEGFR-3 was measured from all cell supernatants and after every purification step. The 
bioassays for monitoring the receptor binding activities use two preB hematopoietic cell lines 
(Ba/F3) expressing chimeric receptors consisting of the extracellular (EC) ligand-binding 
domain of VEGFR-2 or VEGFR-3 and the cytoplasmic domain of mouse erythropoietin 
receptor (EpoR). These Ba/F3 lines, called Ba/F3-VEGFR-2-EpoR (Achen et al., 1998; 
Stacker et al, 1999) and Ba/F3-VEGFR-3-EpoR (Achen et al., 2000), survive and proliferate 
only in presence of interleukin-3 (IL-3). However, signalling from the cytoplasmic EpoR 
domain of chimeric receptors upon ligand binding is capable of rescuing these cells in the 
absence of IL-3. 
 
 In order to detect binding to the EC part of the chimeric receptors, cells were washed free of 
IL-3 with PBS and seeded at a density of 15 000 cells per well to 96 well microtiterplates 
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(Nunc). IL-3 was used as a positive control and cells incubated without IL-3 and 
recombinant proteins were used to determine the background. Because the activities of 
VEGF-A and VEGF-C towards VEGFRs are well known, the produced VEGF-hA165-H6 
and dNdC-hVEGF-C_TEETIK-H6 were used as additional negative and positive controls for 
receptor activity, respectively, when screening activities of rhVEGF-D constructs. To be able 
to evaluate the relative activities of the intermediate and final purification products, standard 
curves were constructed with 0-160 ng/ml rhVEGF-C. Standard curve was prepared 
separately for the different purification intermediates to exclude effects due to different 
buffers used (conditioned medium, dialyzed conditioned medium, 20 mM Tris pH 8.5, 20 
mM Tris-150 mM NaCl pH 8.5, PBS).  
 
Samples  of  rhVEGF-D  were  sterilized  by  filtration  (Millex-GV  PVDF  Durapore  0.22  µm,  
Millipore), diluted 1:25 (except for purified dNdC-VEGF-Dmajor_SIIRR-H6, which was 
diluted 1:10) in cell culture medium (Dulbecco’s modified Eagle’s medium, D-MEM, 
supplemented with 10% (v/v) fetal calf serum, 50mM glutamine and 500?g/ml Neomycin 
for Ba/F3-VEGFR-2-EpoR and 200 ?g/ml Zeocin for Ba/F3-VEGFR-3-EpoR) deficient in 
IL-3. All samples and controls were tested in triplicates and incubations took place at 37°C 
with 5% CO2/95% air. After 48 hours of incubation, 10 ?l of 5 mg/ml MTT solution (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was added to each well. Cells were 
incubated for 2 h after which 100 ?l of lysis buffer was added, and plates were incubated o/n 
at 37°C before measuring the absorbance at 540 nm with a microtiterplate-reading 
spectrophotometer.  
 
4.6 Purification 
The following formulas were utilized in calculation of purification parameters: 
1. yield = total activity (final product, ?g) / total activity (starting material, ?g) 
2. specific activity = relative activity (?g/ml) / protein concentration (?g/ml) 
3. enrichment factor = specific activity (final product) / specific activity 
(starting materia)    
 
4.6.1 Pilot purifications 
Pilot purifications were performed to determine the optimal binding conditions for produced 
recombinant VEGF-D to the ion exchange (IEX) column. All chromatographic procedures 
were carried out at room temperature unless otherwise mentioned. All the dialyses were 
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performed at +4ºC and the buffers were changed every 12 hours for four times. Between 
purification steps, the samples were stored at +4ºC. 
CIEX. Cation exchange (CIEX) chromatography without prior dialysis was performed at pH 
3.0, 3.5, 4.0, 4.5, 5.5, 6.5, 7.5 after 1:1 dilution to CIEX universal buffer using a 1ml SP 
Sepharose Fast Flow column (GEH) at a flow rate of 1 ml/min. Elution was achived with a 
gradient of 0.1 M-1.5 M NaCl.  
CIEX with prior dialysis of the samples was performed at pH 3.0 and 4.0 as described above. 
Samples were dialysed against 0.5x CIEX universal buffer in dialysis tubing with a MWCO 
(Molecular Weight Cut Off) of 3.500 kDa (Spectrum Laboratories Inc.). 
 
AIEX. Anion exchange chromatography (AIEX) without prior dialysis was tested at pH 4.5, 
5.5, 6.5, 7.5 and 8.5. CIEX universal buffer was used at pH 4.5-7.5 and 50 mM Tris-HCl at 
pH 8.5. 1 ml HighTrap DEAE Sepharose Fast Flow columns were used with the same 
parameters as for CIEX.  
AIEX  was  also  carried  out  with  prior  dialysis.  In  order  to  avoid  sample  precipitation,  
samples were first dialysed against 20 mM Tris-HCl, pH 6.5. Then the dialysis was 
continued with pH 7.5, 8.5 (20 mM Tris-HCl) or 9.5 (20 mM Ethanol amine). Dialysed 
samples were subjected to AIEX as described above. 
 
4.6.2 Medium scale two step chromatographic purification of recombinant human 
VEGF-Dmajor -untagged 
First dialysis, binding of sample contaminants and second dialysis.  A volume of 300 ml of 
cell supernatant was first dialysed as previously against 20 mM Tris pH 6.8. Then, 4 ml of 
50% slurry of DEAE Sepharose CL-6B, equilibrated to pH 6.8 was added to the sup for 
binding of sample contaminants (BSC). The mixture was slowly rotated for 2 h at RT. The 
AIEX resin was removed by centrifugation at 5500 g for 30 min and the sup was sterilized 
and subjected to dialysis against 20 mM Tris pH 8.5. The pH of the dialysed sup was 
confirmed at RT and the sample was centrifuged at 16 000 g for 20 min at +4ºC to remove 
possible precipitates that might clog the column.  
AIEX. An Äkta Explorer HPLC-apparatus (GEH) was used for AIEX and size exclusion 
chromatography (SEC) with Unicorn 4.12 chromatography software. The sup was loaded to 
the equilibrated column (1 ml HighTrap DEAE Sepharose FF) at a flow rate of 1.5 ml/min. 
After loading, the column was washed with 15 column volumes of equilibration buffer (20 
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mM Tris pH 8.5).  Samples were eluted with a salt gradient from 0-1 M NaCl in 20 mM Tris 
pH 8.5 over 40 min with a flowrate of 0.5 ml/min. 1 ml fractions were collected.  
Size Exclusion Chromatography (SEC). To remove salts and further purify the sample,  0.5 
ml of the pooled peak fractions resulting from the AIEX step was loaded to an equilibrated 
(20 mM Tris pH 8.5) Superdex 75 10/300 GL column. The flow rate was 0.25 ml/min. 
Ribonuclease A (MW 13 700), Chymotrypsinogen (MW 21 600) and Ovalbumin (MW 
43 000) were used to calibrate the column. 0.5 ml fractions were collected.  
 
Table 8. Purification steps and volumes 
Purification step 
Starting 
volume 
(ml) 
Final 
volume 
(ml) 
Dialysis at pH 6.8 300 375 
Binding of sample 
contaminants (AIEX at pH 6.8) 350 350 
Dialysis at pH 8.5 350 350 
AIEX at pH 8.5 350 2 
SEC at pH 8.5 0.5 1.0 
 
 
4.6.3. Affinity purification of recombinant human VEGF-Dmajor -SIIRR-H6 
Dialysis. 100 ml of sup was sterilized and dialysed as previously described. The dialysis was 
started against PBS pH 6.8 and continued against PBS pH 8.0. The pH was measured and the 
concentration of NaCl in the sup was adjusted from 150 mM (equal to 1x PBS) to 450 mM 
(3x PBS). Possible precipitates were pelleted by centrifugation at 16 000 g for 20 min at 4ºC. 
Affinity chromatography. 325 ?l of equilibrated 50% slurry of Ni-NTA Superflow Sepharose 
was added to 100 ml of sup and gently rotated o/n at +4ºC. The resin was rescued by 
centrifugation at 5500 g for 30 min at +4ºC and loaded to a Poly-Prep Chromatography 
Column (Biorad). The column was washed with 20 column volumes of 3x PBS containing 
5% glycerol and with 20 column volumes of 3x PBS containing 5% glycerol and 20 mM 
imidazole. Elution of bound proteins was achived with 3x PBS containing 5% glycerol and 
240 mM imidazole. 0.5 ml fractions were collected, of which SDS-PAGE analysis was 
performed. The peak fractions were identified by silver staining of the gel. These fractions 
were pooled and dialyzed against 1x PBS. After sterilization by filtration (Millex-GV PVDF 
Durapore 0.22 µm, Millipore), the sample was stored frozen at -70ºC. 
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5. RESULTS 
5.1 Expression vector constructs  
Sequencing of expression vectors revealed that some of the constructs carried two inserts in 
tandem. However, these vectors were expected to express the desired polypeptide; 
consequently  they  were  utilized.  Maps  of  all  expression  constructs  can  be  found  from  
Appendix I. Commercially available single cutting restriction enzymes are indicated on these 
maps. 
 
5.2 Expression 
Expression of recombinant VEGF-D. Transfected S2-cells produced variable amounts of 
recombinant VEGF-D. Produced proteins are named as the construct that produced them 
except for the vector part (for example, construct pAc5-BiP-dNdC-hVEGF-
Dmajor_untagged produces dNdC-hVEGF-Dmajor_untagged). Examples of low, medium 
and high expression levels of untagged constructs are shown in Figure 11. The location of 
the selection marker (in the same expression vector versus in a separate selection vector 
cotransfected with the expression vector) did not have an obvious effect on expression levels. 
Monoclonal antibody against mouse VEGF-D could be used for the IP and Western blotting 
since  anti-mouse  VEGF-D  antibody  shows  40%  cross-reactivity  with  human  VEGF-D  
(according to supplier) (and anti-human VEGF-D antibody was temporarily unavailable).  
 
1. Negative control
2. Low: pAc5-BiP-dNdC-
hVEGF-Dminor_untaggged
3. High: pAc5Hygro-BiP-dNdC-
hVEGF-Dminor_untagged
4. Medium: pAc5-BiP-dNdC-
hVEGF-Dmajor_untagged
Figure 11. Western blot of cell supernatants harvested 3 days
post-transfention showing low, highand medium expression
levels of untagged rhVEGF-D (IP with a-mVEGF-D Ab).
4.3.2.1.
20-
kDa
 
 
5.3 Protein analysis 
Determination of protein concentration. Protein concentrations were measured with both the 
Biorad Protein assay and the BCA protein assay. The determination of the protein 
concentration of cell supernatant was impossible with either of these assays. Hence the 
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protein concentration of dialysed samples is used instead of that of the starting material 
(Table 10). 
 
Table 9. Protein concentrations. 
Sample Step 
Protein 
concentration 
(mg/ml) 
Total 
protein 
(mg) 
dNdC-hVEGF-Dmajor_ 
untagged 
Dialyzed 
intermediate 0.46 173 
  Final product 3.52 15 
dNdC-hVEGF-Dmajor_ 
SIIRR-H6 
Dialyzed 
intermediate 0.70 70 
  Final product 0.18 0.45 
 
 
MTT-Ba/F3-assay. To verify the biological activity of recombinant human VEGF-Ds with 
VEGFR-2 and VEGFR-3, a bioassay was performed using the cell lines Ba/F3-VEGFR-2-
EpoR  and  Ba/F3-VEGFR-3-EpoR.  In  absence  of  IL-3,  these  cell  lines  can  survive  and  
proliferate only in presence of growth factors capable of dimerizing the extracellular 
domains of VEGFR-2 or VEGFR-3. Cell survival was determined by the colorimetric MTT-
assay which measures mitochondrial activity in viable cells (Mosmann, 1983). Based on the 
Ba/F3-VEGFR-3 assay results for transiently transfected cell supernatans (Figure 12), two 
rhVEGF-Dmajor constructs were selected for purification (pAc5-BiP-dNdC-hVEGF-
Dmajor_untagged and pAc5Hygro-BiP-dNdC-hVEGF-Dmajor_SIIRR-H6). None of the 
minor forms were able of dimerizing the VEGFR-3/EpoR in the Ba/F3 assay. The activity of 
purified dNdC- hVEGF-Dmajor_SIIRR-H6 declined remarkably during the purification 
process (Figure 14). Similarily rhVEGF-Dmajor_untagged lost practically all its activity 
towards VEGFR-3 (Figure 13) during the last purification step. Activities of all purification 
intermediates and final product are shown in Figure 13. Note that the activities are relative 
activities, indicating the concentration of VEGF-C needed to reach equal activity (Figures 
12-14, Tables 10 and 11). 
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Figure 12. Testing the activity of rhVEGF-D constructs. Only  two  of  the  rhVEGF-Ds  
significantly promoted cell survival. Errorbars indicate 2 SDs.  
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Bioassays of pAc5-BiPdNdC-VEGF-Dmajor_SIIRR-H6 purification and 
VEGF-D from R&D Systems
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Figure 14. Bioassay of dNdC-hVEGF-Dmajor_SIIRR-H6 and commercial rhVEGF-D. 
Standard curves with VEGF-C are indicated in blue (Ba/F3-VEGFR-3/EpoR-assay in light 
blue and Ba/F3-VEGFR-2/EpoR-assay in dark blue).   dNdC-VEGF-Dmajor_SIIRR-H6 is 
indicated in red and commercial rhVEGF-D from R&D is in green. Sample activities 
towards each receptor are shown after the corresponding standard curve. The activity of 
dNdC-hVEGF-Dmajor_SIIRR-H6 cell supernatant was not measured with Ba/F3-VEGFR-
2/EpoR-assay. A concentration of 160 ng/ml commercial rhVEGF-D (R&D) was 
comparable in its activity towards VEGFR-3 and VEGFR-2 with approximately 1.8 ng 
VEGF-C and 30 ng VEGF-C, respectively.  
 
Table 10. Relative activities, dNdC-hVEGF-Dmajor_ untagged 
 relative activity towards  
VEGFR-2 
(µg VEGF-C/ml) 
yield of VEGFR-2 activity 
(%) 
enrichment of 
VEGFR-2 activity 
starting material 0.1   
final product 0.363 5.2* 0.475* 
 relative activity towards  
VEGFR-3 
(µg VEGF-C/ml) 
yield of VEGFR-3 activity 
(%) 
enrichment of 
VEGFR-3 activity 
starting material 0.013   
final product 0 0* 0* 
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Table 11. Relative activities, dNdC-hVEGF-Dmajor_ SIIRR-H6 
 relative activity towards  
VEGFR-2 
(µg VEGF-C/ml) 
yield of VEGFR-2 activity 
(%) 
enrichment of 
VEGFR-2 activity 
starting material    
final product 0.28   
 relative activity towards  
VEGFR-3 
(µg VEGF-C/ml) 
yield of VEGFR-3 activity 
(%) 
enrichment of 
VEGFR-3 activity 
starting material 0.008   
final product 0.05 16.7 24.3 
*If the calculation had been based on protein amount instead of protein activity, values for both yield 
and enrichment would be significantly higher indicating a better purification procedure. However, 
this would ignore the loss of activity. The differential loss of activity towards VEGFR-2 versus 
VEGFR-3 is one of the major findings of this study (see discussion). Nevertheless, even inactive 
protein can be used for some applications such as immunization for the production of antibodies. 
 
 
 
5.4 Purification of dNdC-hVEGF-Dmajor_untagged 
Based on the results of the pilot purification, low ionic strength and thus dialysis appeared to 
be required for efficient binding of rhVEGF-Dmajor_untagged to CIEX or AIEX columns. 
The volume of cell supernatant grew by 25% during dialysis. After dialysis, VEGF-D bound 
to the cation exchanger SP Sepharose at pH 3.0 and 4.0 as well as to the DEAE Sepharose at 
pH  7.5,  8.5  and  9.5.  In  all  these  conditions  VEGF-D  started  already  to  elute  at  NaCl  
concentrations  of  about  0.1  M  (Figure  15).  AIEX  at  pH  8.5  was  selected  for  the  upscaled  
purification. The binding of VEGF-D increases with the pH and pH 8.5 appeared a good 
compromise offering sufficient binding strength while not endangering the protein integrity 
(cystine knot) due to the high pH.  
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15. Silver stained SDS-PAGE gels of pilot purification fractions. dNdC-hVEGF-
Dmajor_untagged migrates as a fragment just below the standard of 20kDa. SAB- 
Supernatant after binding. 
  
 
Medium scale purification of dNdC-hVEGF-Dmajor_untagged. Anion exchange 
chromatography  was  used  with  20  mM  Tris  at  pH  8.5  as  a  buffer.  dNdC-hVEGF-
Dmajor_untagged bound efficiently to the column because there was only very little or no 
flow through of VEGF-D when loading and washing the AIEX column. The peak fraction of 
AIEX pH 9.5 
1. Sup 
2. LMW marker 
3. SAB 
4. 1st wash 
5. 0.1M 
6. 0.2M 
7. 0.3M 
8. 0.4M 
9. 0.5M 
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1.    2.    3.   4.    5.    6.   7.   8.   9.  10.  11. 12.  13.  14.  15.      
AIEX pH 8.5 
1.    2.    3.   4.    5.    6.   7.   8.   9.  10.  11. 12.  13.  14.  15.      
1. Sup 
2. SAB 
3. Rainbow marker 
4. 1st wash 
5. 0.1M 
6. 0.2M 
7. 0.3M 
8. 0.4M 
9. 0.5M 
10. 0.6M 
11. 0.7M 
12. 0.8M 
13. 0.9M 
14. 1.0M 
15. 1.5M 
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3. 1st wash  
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dNdC-hVEGF-Dmajor_untagged eluted from the column at 135 mM NaCl (Figure 16). 
Based on Western blot, five 1 ml fractions from 103 mM to 230 mM NaCl contained almost 
all of the VEGF-D. The fractions from 135 mM to 167 mM were pooled and used for SEC 
and protein assays. The peak fraction of dNdC-hVEGF-Dmajor_untagged eluted from the 
SEC column roughly at the same volume as Chymotrypsinogen (MW 21 600) which was 
used for calibration. The two peak fractions with the highest amounts of dNdC-hVEGF-
Dmajor_untagged were pooled and used for further experiments. The purities and activities 
of all purification intermediates are indicated in the purification tables (Tables 9, 10 and 11). 
Figure 17 shows Western blot of samples from the two last purification steps. 
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rhVEGF-D samples after 
AIEX and SEC and 
commercial hVEGF-D. The 
arrows indicate the upper band of 
VEGF-D present in AIEX peak 
fraction but appears to be 
missing from SEC fraction (see 
discussion). LMW- Low 
molecular weigth marker. 
Figure 16. Silver staining of 
SDS-PAGE gels of AIEX 
fractions. 10 µl of each fraction 
was loaded. Arrows indicate the 
upper band that elutes sligthly later 
than the main fraction of VEGF-D 
(see discussion).  
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5.5 Affinity purification of dNdC-hVEGF-Dmajor_SIIRR-H6 
No flow through of dNdC-hVEGF-Dmajor_SIIRR-H6 was detected during loading and 
washing without imidazole (Figure 18). Some rhVEGF-D eluted at 20mM imidazole, but the 
majority of dNdC-hVEGF-Dmajor_SIIRR-H6 eluted with 240mM imidazole (Figure 18). 
Elution fractions 3-7 were pooled and used for further experiments. 
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Figure 18. Silver stained SDS-PAGE gel visualizing the affinity purification of dNdC-
hVEGF-Dmajor_SIIRR-H6.  Fractions 3-7 were pooled and used for protein concentration 
and receptor affinity determinations. SUP- Cell supernatant, SAB- Supernatant after binding.            
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6. DISCUSSION 
Many reports have shown the function of VEGF-D in vivo. In absence of functional, 
commercially available VEGF-D, the constructs used in these studies have been highly 
variable. A closer look shows that VEGF-D activity has been shown by stimulating rabbit or 
human tissues with murine VEGF-D (Marconcini et al.,1999) and using human VEGF- D to 
stimulate rabbit and rat tissues (Rissanen et al. 2003, ; Byzova et al., 2002). As human and 
murine VEGF-D display a differential binding pattern to VEGFR-2 (Baldwin et al., 20011), 
the functions of VEGF-D cannot be easily extrapolated from one species to another. The aim 
of this study was to produce and purify high quality biologically active VEGF-D, equal to 
the naturally occurring form. This protein could then be used to study VEGF-D activity. The 
results of the study are discussed below. 
 
6.1 Cloning and expression 
VEGF-D  constructs  were  created  by  PCR  which  offered  the  possibility  to  easily  generate  
alternative N- and C-terminal ends. Vectors were designed in such a fashion that there would 
be no heterologous amino acids in the N-terminus after cleavage of the signal peptide (BiP). 
Although the cloning procedures were quite straightforward, some constructs were found to 
contain two inserts in tandem. This was most likely due to too high amounts of insert in the 
ligation preceded by incomplete inactivation of the Klenow polymerase. After digestion with 
SapI, active residual Klenow polymerase presumably filled the 5’/3’sticky end and this 
blunt-ended fragment likely ligated between the blunt 3’-end of the first insert and the blunt 
5’-end of the vector. 
 
Insect cells were chosen for protein expression because they are inexpensive and production 
of proteins similar to VEGF-D has been successful in previous experiments (VEGF-C: 
Kärpänen et al., 2006). Although the transfected insect cells did produce active VEGF-D, the 
expression levels were not very high. Due to serious sensitivity problems experienced with 
Western blot with the pentahistidine antibody, the expression levels of His-tagged constructs 
could not be determined. However, the target was to find a construct that would produce 
active VEGF-D, therefore the constructs were selected for further experiments based on the 
activity assay of cell supernatants instead of the total VEGF-D amount. In addition, the aim 
was to produce VEGF-D equal to the naturally occurring form, hence the untagged forms 
were preferred. 
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6.2 Biological activities of the produced VEGF-Ds 
VEGF-D binds to and activates both VEGFR-2 and VEGFR-3 (Achen et al., 1998). In vivo, 
the full-length form of VEGF-D is processed upon secretion (Stacker et al., 1999). VEGF-D 
has two alternative N-terminal cleavage sites, resulting in two different mature forms (major 
and minor). The fully processed, mature form of VEGF-D has greater affinity to both 
VEGFRs than does the full-length form (Stacker et al., 1999). In almost all previous 
experiments on the receptor binding activity of mature VEGF-D, the same major-FLAG-
tagged construct was used (VEGF-DdNdC-FLAG, Achen et al., 1998). This mature form of 
VEGF-D was shown to have ~290- and ~40-fold greater affinity for VEGFR-2 and VEGFR-
3, respectively, when compared with the full-length form of VEGF-D (Stacker et al., 1999). 
However,  this  form  does  not  correspond  to  any  naturally  occurring  form.  There  are  no  
reports about the activity of any form of VEGF-Dminor. In addition, it must be kept in mind 
that receptor binding activity is not necessarily the same as the capacity to activate the 
receptor. Because the significance of the two alternative N-terminal processing sites is still 
unknown of VEGF-D, both minor and major constructs were included in this study.   
 
The Ba/F3-bioassay was used to test the activities of produced and purified VEGF-Ds. It was 
also used to determine which constructs were chosen for the upscaled purifications. The 
activities of cell supernatants were initially tested only with the Ba/F3-VEGFR-3-EpoR-
assay. Interestingly, none of the minor forms were able to activate VEGFR-3/EpoR-chimeras 
in the Ba/F3-assay. Based on Western blot, at least the untagged minor forms were expressed 
in similar or higher levels than the major forms (Figure 11), so the failure to activate 
VEGFR-3 did not result from lack of expression. In addition, minor forms successfully 
bound VEGFR-3/IgG (immunoprecipitation prior to Western blot, Table 6. Western blot 
results were similar to that in Figure 11, data not shown) indicating that minor forms do bind 
to,  but  might  not  be  able  to  activate  VEGFR-3.  From  the  tested  major  forms,  only  two  
constructs did yield protein that activated VEGFR-3/EpoR chimera in the Ba/F3-assay. Both 
of these forms were selected for upscaled purification.  
 
6.3 Purification 
Based on previous experiments (personal communication by Michael Jeltsch) it was 
expected that VEGF-D is – similar to VEGF-B and unlike VEGF-C – difficult to purify 
without  loss  of  biological  activity.  Therefore  the  aim  was  to  use  as  few  and  as  gentle  
purification steps as possible. Before dialysis, our protein bound neither cation nor anion 
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exchange chromatography columns in a pH range from 3.0 to 9.5. After lowering the ionic 
strength by dialysis, the conditions were found in which dNdC-hVEGF-Dmajor_untagged 
bound efficiently to a DEAE Sepharose Fast Flow AIEX column. A pH as high as possible 
without compromising the biological activity was chosen for upscaled purification. 
 
The activity and the protein concentration of the sample were determined before and after 
each purification step. Note that the purification intermediate collected after dialysis (or 
dialyzed sup) was collected after dialysis at pH 6.8. By mistake, no aliquots were collected 
after the step “binding of sample contaminants” (AIEX at pH 6.8). As can be seen from 
Figure 19, significant amounts of contaminants were removed by this step. 
 
 
 
 
During these experiments, the band of dNdC-hVEGF-D migrated in SDS-PAGE faster than 
expected (Stacker et al., 1999). This could be due to differential glycosylation originating 
from the use of insect cell line, although successful production of glycosylated cytokines has 
been reported previously (Johanson et al., 1995; Lehr et al., 2000).  
 
Expression of mature VEGF-D without the flanking propeptides could result in insufficient 
dimerization if N- and C-terminal extensions contribute to this event as proposed in Figure 7.  
Insufficient dimerization and dimer breakdown during purification procedures could also 
explain the poor receptor activation.  
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Intepreting the purification results: 
1. Exact determination of the protein concentration of the cell supernatant appeared 
impossible. Most likely some compound in the insect cell growth medium interfered with 
the protein concentration assays, causing the saturation of the used colorimetric assays 
already at low values of the standard curve. Hence, the standard curve was not in linear 
range and the regression curve could not be trusted. Both Biorad Protein assay and BCA 
protein  assay  were  tried  with  similar  results.  Therefore,  the  protein  concentration  of  
dialyzed purification intermediate was used in calculations. Visually estimated, the 
protein amounts of the sup (starting material) and the dialyzed sample seem very similar 
(Figure 19). With other samples, results from Biorad Protein assay and BCA protein 
assay were highly consistent, although values were slightly higher in Biorad protein 
assay. 
2. The salt or other inhibitory agent in cell culture medium presumably affected also 
receptor binding activities since the relative activities towards both receptors were higher 
in dialyzed purification intermediate than in the cell supernatant (Figure 13; note that the 
sample volume grew during dialysis - the dialyzed intermediate should be more dilute 
than the cell supernatant).  
3. Receptor activities were quantitated relative to VEGF-C activities because there is no 
biologically significantly active VEGF-D to compare to. All commercially available 
forms are more or less unequal to the naturally occurring one (Table 2) and largely 
biologically inactive at least towards VEGFR-3 (Mäkinen et al., 2001; Figure 14). Hence 
the  activities  measured  in  this  study  were  compared  to  VEGF-C.  The  use  of  relative  
activities (relative to a reference VEGF-C standard) caused that the calculation of 
specific activity (total amount of activity/total protein amount) was only meaningful to a 
limited degree; the activities were not actual values of mass.    
4. In  the  final  step  (SEC),  all  activity  towards  VEGFR-3  was  lost  (Figure  13).  The  same  
sample was used for the VEGFR-2 affinity determination, the tests were made 
simultaneously and all controls, standards and other samples confirmed that the 
experiment was reliable. This indicates that during the last purification step, dNdC-
hVEGF-Dmajor_untagged gets somehow modified, leading to an incapability to activate 
VEGFR-3. This could be due to some residual proteolytic activity during purification and 
will be discussed in detail below. 
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6.4 Conclusions  
The role of differential N-terminal processing of VEGF-D is still unknown, but if the minor 
form binds, but fails (completely or partially) to activate VEGFR-3 (as this study indicates), 
it could work as a competitive inhibitor or partial agonist for VEGF-C/VEGF-Dmajor- 
VEGFR-3 activation. In addition, if activities of cell sups had been tested with the Ba/F3-
VEGFR-2/EpoR-assay, would there have been activity found from the minor forms?  
 
As the purification proceeded, the activity of VEGF-D towards its receptors decreased. The 
very low specific activity of the samples after AIEX indicates that the major band (Figures 
16 and 17) might not be the one that is responsible for the activity. Another band of VEGF-D 
was detected just above the majority of VEGF-D in SDS-PAGE (Western blot, Figure 17). If 
the VEGF-D migrating as this weaker band was responsible for VEGFR-3/EpoR activation, 
the loss of activity during SEC could be explained since this weaker band cannot be detected 
in final products. This band eluted right after the major VEGF-D peak in AIEX (i.e. with 
higher salt concentration, Figure 16). In anion exchange chromatography, negatively charged 
(acidic) residues cause tighter binding, hence the weaker band is more acidic than the major 
band.  The  N-terminal  part  of  VEGF-D major  contains  two acidic,  whereas  the  C-terminus  
contains four basic amino acids. Thus cleavage of the N-terminus leads to a smaller protein 
with a less negative charge (Figure 20). Presumably there is some residual proteolytic 
activity during purifications and due to the final step, all the produced dNdC-hVEGF-
Dmajor_untagged might be cleaved at the N-terminus similar to the minor form. If only the 
major form was responsible for the activation of VEGFR-3, the fact that no activity of the 
minor forms towards VEGFR-3 was detected (Figure 12) could be explanained. If this 
hypothesis can be verified, the role of the alternative N-terminal cleavage becomes obvious: 
By  proteolysis  the  activity  of  VEGF-D  can  be  redirected  from  the  lymphatics  towards  the  
blood vessels.  
 
 
  
Figure 20. Schematic representation of the cleavage sites of mature VEGF-D. Acidic 
amino acids are highlighted in red and are found in the N-teminal region whereas basic 
amino acids, which are highlighted in blue, are found in the C-terminal region. 
N- -C FAATFYDIETLKVID…                                    …RHPYSIIRR 
major minor major and minor 
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6.5 Future experiments 
First the activity of VEGF-Dminor towards the VEGFR-2 should be tested. Ba/F3-VEGFR-2 
assay  would  enlighten  the  binding  capacity  but  a  phoshorylation  assay  with  porcine  aortic  
endothelial (PAE) cells over-expressing native VEGFR-2 would be more reliable. Mass 
spectrometric analysis could be used to determine whether any or what kind of proteolytic 
activity took place during purification. The dimerization status of various purification 
intermediates should also be determined.  
 
There are many possible ways to reach higher yield of active target protein. These include 
the use of a higher resolution column, or using an alternative chromatographic step instead of 
size exclusion chromatography. Alternative purification methods to test include also other 
chromatographic methods such as hydrophobic interaction, hydroxyapatite or lectin -, 
heparin -, and dye-affinity columns. Purification could be started with bulk precipitation of 
sample contaminants. In addition, performing all purification steps at low temperature would 
decrease the activity of proteolytic enzymes and increase the target integrity. 
 
Different expression systems (expression vectors, promoters, signal sequences, inducible 
expression, different cell lines etc.) could also be tested to find a construct with higher 
expression levels to start with. Another cell line should be tried that does not cleave VEGF-D 
at the N-terminus (for example Sf-9 insect cells). New methods for testing protein 
concentration, for example densitometric analysis or fluorescent labelling should be tried in 
order to determine the protein concentration of the sup. There are also alternative methods 
for determining the activity of VEGF-D. In fact, the induction of VEGFR-3 using PAE-cells 
over-expressing native VEGFR-3 and stimulation of human dermal microvascular 
endothelial cells were tested to determine the activity of VEGF-D, but both of these proved 
more laborious and expensive than Ba/F3-bioassay. In addition, the above mentioned assays 
would have been only semiquantitative, making calculations very difficult. However, these 
assays would have shown the activity towards native VEGFRs, which might differ from that 
of chimeric receptors used in the Ba/F3-assay. 
 
It is important to remember that VEGF-D is just one molecule in the complicated signalling 
network that determines the fate of cells and tissues and eventually the faith of the whole 
organism. With modern techniques such as microarrays it has become possible to 
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simultaneously study the expression of thousands of genes in a given tissue or developmental 
stage of an organism. However, elucidating the effects of individual molecules is essential 
for understanding the basic biology of living organisms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60
7. REFERENCES 
 
Aase K., von Euler G., Li X., Ponten A., Thoren P., Cao R., Cao Y., Olofsson B., Gebre-Medhin S., Pekny 
M., Alitalo K., Betsholtz C., Eriksson U. (2001). Vascular endothelial growth factor-B-deficient 
mice display an atrial conduction defect. Circulation 104(3), 358-64. 
Achen M.G and Stacker S.A.  (2006). Tumor lymphangiogenesis and metastatic spread - New players begin 
to emerge. International journal of cancer119(8):1755-60. 
Achen M.G., Roufail S., Domagala T., Catimel B., Nice E.C., Geleick D.M., Murphy R., Scott A.M., 
Caesar C., Makinen T., Alitalo K., Stacker S.A. (2000). Monoclonal antibodies to vascular 
endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. 
European Journal of Biochemistry 267(9), 2505-15. 
Achen M.G., Williams R.A., Minekus M.P., Thornton G.E., Stenvers K., Rogers P.A., Lederman F., 
Roufail S., Stacker S.A. (2001). Localization of vascular endothelial growth factor-D in malignant 
melanoma suggests a role in tumour angiogenesis. The Journal of pathology 193(2):147-54. 
Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. (1998). 
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 
(Flk1) and VEGF receptor 3 (Flt4). Proceedings of the National Academy of Sciences of the United 
States of America  95(2), 548-53. 
Alitalo K., Tammela T., Petrova T.V.. (2005). Lymphangiogenesis in development and human disease. 
Nature,  438(7070):946-53. 
Angel P., Karin M. (1991). The role of Jun, Fos and the AP-1 complex in cell-proliferation and 
transformation. Biochimica et biophysica acta 1072(2-3), 129-57. 
Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., 
De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., 
Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., 
Persico G., Herbert J.M., Communi D., Shibuya M., Collen D., Conway E.M., Carmeliet P. 
(2003). Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and 
Flk1. Nature Medicine  9(7), 936-43. 
Avantaggiato V., Orlandini M., Acampora D., Oliviero S., Simeone A. (1998). Embryonic expression 
pattern of the murine figf gene, a growth factor belonging to platelet-derived growth factor/vascular 
endothelial growth factor family. Mechanisms of development 73(2):221-4. 
Baldwin M.E., Halford M.M., Roufail S., Williams R.A., Hibbs M.L., Grail D., Kubo H., Stacker S.A., 
Achen M.G. (2005). Vascular endothelial growth factor D is dispensable for development of the 
lymphatic system. Molecular and cellular biology 25(6), 2441-9. 
Baldwin M.E., Catimel B., Nice E.C., Roufail S., Hall N.E., Stenvers K.L., Karkkainen M.J., Alitalo K., 
Stacker S.A., Achen M.G. (20011). The specificity of receptor binding by vascular endothelial growth 
factor-d is different in mouse and man. Journal of Biological Chemistry 276(22), 19166-71.  
Baldwin M., Roufail S., Halford M.M., Alitalo K., Stacker S.A., Achen M.G. (20012)Multiple forms of 
mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. Journal of 
Biological Chemistry 276(47), 44307-14.  
Baldwin H.S. (1996).  Early embryonic vascular development. Cardiovascular Research. Spec No:E34-45.  
Beltramo E., Pomero F., Allione A., D'Alu F., Ponte E., Porta M. (2002). Pericyte adhesion is impaired on 
extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia. 45(3), 
416-9. 
Byzova T.V., Goldman C.K., Jankau J., Chen J., Cabrera G., Achen M.G., Stacker S.A., Carnevale K.A., 
Siemionow M., Deitcher S.R., DiCorleto P.E. (2002). Adenovirus encoding vascular endothelial 
growth factor-D induces tissue-specific vascular patterns in vivo. Blood 99(12), 4434-42. 
Cao, Y., Chen, H., Zhou, L., Chiang, M. K., Anand-Apte, B., Weatherbee, J. A., Wang, Y., Fang, F., 
Flanagan, J. G., and Tsang, M. L. (1996). Heterodimers of placenta growth factor/vascular 
endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-
1/KDR. Journal of Biological Chemistry 271, 3154-62. 
Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., 
Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher 
S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., 
Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. (2001) Synergism 
between vascular endothelial growth factor and placental growth factor contributes to angiogenesis 
and plasma extravasation in pathological conditions. Nature Medicine 7(5), 575-83. 
Carmeliet P. and Jain R. K. (2000).  Angiogenesis in cancer and other diseases. Nature 407, 249-257. 
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., 
Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., 
 61
Risau, W., and Nagy, A. (1996). Abnormal blood vessel development and lethality in embryos 
lacking a single VEGF allele. Nature 380, 435-9. 
Cavallaro U, Liebner S, Dejana E. (2006). Endothelial cadherins and tumor angiogenesis. Experimental cell 
research 312(5), 659-67.  
Chung Y.T., Keller E.B. (1990). Positive and negative regulatory elements mediating transcription from the 
Drosophila melanogaster actin 5C distal promoter. Molecular and Cellular Biology 10(12):6172-80. 
Clark E.R. and Clark E.L. (1932). Observations on the new growth of lymphatic vessels as seen in 
transparent chambers introduced into the rabbit's ear. American Journal of Anatomy  51(1),  49-87. 
Coffin J.D., Harrison J., Schwartz S., Heimark R. (1991). Angioblast differentiation and morphogenesis of 
the vascular endothelium in the mouse embryo. Developmental biology 148(1),  51-62. 
Coffin, J.D., and Poole, T.J. (1988). Embryonic vascular development: immunohistochemical identification of 
the origin and subsequent morphogenesis of the major vessel primordia in quail embryos. 
Development 102, 735-48. 
Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand 
SJ, Streilein JW. (2004). VEGF-A stimulates lymphangiogenesis and hemangiogenesis in 
inflammatory neovascularization via macrophage recruitment. The Journal of clinical investigation 
113(7), 1040-50. 
Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., 
Radziejewski C., Maisonpierre P.C., Yancopoulos G.D. (1996). Isolation of angiopoietin-1, a 
ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87(7), 1161-9. 
Dignam S.S., Case S.T. (1990). Balbiani ring 3 in Chironomus tentans encodes a 185-kDa secretory protein 
which is synthesized throughout the fourth larval instar. Gene 88(2), 133-40. 
Dumont D.J., Jussila L., Taipale J., Lymboussaki A., Mustonen T., Pajusola K., Breitman M., Alitalo K. 
(1998). Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science  30, 946-9. 
Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. (1995). Vascular permeability factor/vascular 
endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of 
Pathology 146, 1029-39. 
Ebos J.M., Bocci G., Man S., Thorpe P.E., Hicklin D.J., Zhou D., Jia X., Kerbel R.S. (2004). A naturally 
occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human 
plasma. Molecular Cancer Research 2(6), 315-26. 
Enholm B., Paavonen K., Ristimaki A., Kumar V., Gunji Y., Klefstrom J., Kivinen L., Laiho M., 
Olofsson B., Joukov V., Eriksson U., Alitalo K. (1997). Comparison of VEGF, VEGF-B, VEGF-C 
and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene.14(20), 
2475-83. 
Ferrara N., Gerber HP., LeCouter J.  (2003). The biology of VEGF and its receptors. Nature Medicine 9(6), 
669-76.  
Ferrara N. and Davis-Smyth T. (1997). The biology of vascular endothelial growth factor. Endocrine reviews 
18(1), 4-25. 
Ferrara N., Carver-Moore K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. 
J., and Moore, M. W. (1996). Heterozygous embryonic lethality induced by targeted inactivation of 
the VEGF gene. Nature 380, 439-42Folkman J. (1971). Tumor angiogenesis: therapeutic 
implications. New England Journal of Medicine 285, 1182-6. 
Folkman J. and Shing Y. (1992).  Angiogenesis. Journal of biological chemistry 267, 10931-10934. 
Folkman J. (1995). Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nature Medicine1,  27-
31. 
Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. (1995). Role of the Flt-1 receptor tyrosine kinase in 
regulating the assembly of vascular endothelium. Nature 376(6535), 66-70. 
Gasmi A., Abidi F., Srairi N., Oijatayer A., Karoui H., Elayeb M.  (2000). Purification and characterization 
of a growth factor-like which increases capillary permeability from Vipera lebetina venom. 
Biochemical and biophysical research communications 268(1), 69-72. 
Gilbert S. F. (1991). Heart and circulatory system. In Developmental Biology, (Sunderland: Sinauer), 219 
Gimbrone M. A., Jr., Leapman S. B., Cotran R. S., and Folkman J. (1972). Tumor dormancy in vivo by 
prevention of neovascularization. Journal of Experimental Medicine 136, 261-76. 
Gleadle J. M., Ebert B. L., Firth J. D., and Ratcliffe P. J. (1995). Regulation of angiogenic growth factor 
expression by hypoxia, transition metals, and chelating agents. American Journal of Physiology 268, 
C1362-8. 
Grieb T.A., Burgess W.H. (2000). The mitogenic activity of fibroblast growth factor-1 correlates with its 
internalization and limited proteolytic processing. Journal of Cellular Physiology 184(2):171-82. 
 62
Gritz L und Davies J. (1983).  Plasmid-encoded hygromycin B resistance: the sequence of hygromycin B 
phospho-transferase gene and its expression in Escherichia coli and Saccharomyces cerevisiae. Gene 
25, 179-188. 
Hanahan D., and Folkman J. (1996). Patterns and emerging mechanisms of the angiogenic switch during 
tumorigenesis. Cell 86, 353-64. 
Harper DR, Murphy G. (1991). Nonuniform variation in band pattern with luminol/horseradish peroxidase 
western blotting. Analytical Biochemistry 192(1), 59-63. 
Heldin C.H., Westermark B. (1999). Mechanism of action and in vivo role of platelet-derived growth factor. 
Physiological reviews 79(4), 1283-316. 
Herzog Y., Kalcheim C., Kahane N., Reshef R., Neufeld G. (2001). Differential expression of neuropilin-1 
and neuropilin-2 in arteries and veins. Mechanisms of development 109(1), 115-9. 
His W. (1900). Lecithoblast und Angioblast der Wirbelthiere. Akademie der Wissenschaften 22, 171-328. 
Huang K., Andersson C., Roomans G.M., Ito N., Claesson-Welsh L. (2001) Signaling properties of VEGF 
receptor-1 and -2 homo- and heterodimers. The international journal of biochemistry & cell biology 
33, 315-324.  
Hubbard SR. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with 
peptide substrate and ATP analog. EMBO J. 16(18), 5572-81. 
Hudgins, W. R., Hampton, B., Burgess, W. H., and Perdue, J. F. (1992). The identification of O-
glycosylated precursors of insulin-like growth factor II. Journal of Biological Chemistry 267, 8153-60. 
Huntington G.S. 1908. The genetic interpretation of the development of the mammalian lymphatic system. 
The Anatomical Record 2,  19-46.  
Ishii H., Yazawa T., Sato H., Suzuki T., Ikeda M., Hayashi Y., Takanashi Y., Kitamura H. (2004). 
Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by 
vascular endothelial growth factors (VEGFs). Lung Cancer  45:, 325-37.  
Jackson D.G., Prevo R., Clasper S., Banerji S. (2001). LYVE-1, the lymphatic system and tumor 
lymphangiogenesis. 
Trends in immunology 22(6), 317-21. 
Jain R.K., Carmeliet P.F. (2001). Vessels of death or life. Scientific American 285(6), 38-45. 
Jain R.K, Fenton B.T. (2002). Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? 
Journal of the National Cancer Institute 94(6), 417-21. 
Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain 
R.K., Alitalo K. (1997). Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. [Erratum in: 
Science 1997 Jul 25;277(5325):463]. Science. 276(5317), 1423-5.  
Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I. (2004). Vascular endothelial growth 
factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological 
function in vascular endothelial cells. [Erratum in: J Biol Chem. 2006 Feb 24;281(8):5328.]. Journal 
of Biological Chemistry 279(34), 36148-57.  
Johansen H., van der Straten A., Sweet R., Otto E., Maroni G., Rosenberg M. (1989). Regulated 
expression at high copy number allows production of a growth-inhibitory oncogene product in 
Drosophila Schneider cells. Genes & development 3(6):882-9. 
Johanson K., Appelbaum E., Doyle M., Hensley P., Zhao B., Abdel-Meguid S.S., Young P., Cook R., 
Carr S., Matico R., et al. (1995). Binding interactions of human interleukin 5 with its receptor alpha 
subunit. Large scale production, structural, and functional studies of Drosophila-expressed 
recombinant proteins. Journal of Biological Chemistry 270(16), 9459-71. 
Joukov V., Sorsa T., Kumar V., Jeltsch M., Claesson-Welsh L., Cao Y., Saksela O., Kalkkinen N., Alitalo 
K. (1997). Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO 
Journal 16(13), 3898-911. 
Joukov. V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo 
K. (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) 
and KDR (VEGFR-2) receptor tyrosine kinases [published erratum appeared in EMBO J 1996 Apr 
1;15(7):1751]. EMBO Journal 15, 290-98. 
Junqueira-de-Azevedo Ide L., da Silva M.B., Chudzinski-Tavassi A.M., Ho P.L. (2004). Identification and 
cloning of snake venom vascular endothelial growth factor (svVEGF) from Bothrops erythromelas 
pitviper. Toxicon : official journal of the International Society on Toxinology 44(5), 571-5. 
Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M., 
Alitalo K. (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic 
endothelium during development. Proceedings of the National Academy of Sciences of the United 
States of America 92(8):3566-70. 
Kampmeier O.F. (1912). The value of the injection method in the study of lymphatic development. The 
Anatomical record 6,  223-233. 
 63
Kendall R.L., Thomas K.A. (1993). Inhibition of vascular endothelial cell growth factor activity by an 
endogenously encoded soluble receptor.  Proceedings of the National Academy of Sciences of the 
United States of America 90(22), 10705-9. 
Kerr, D.J. (2004). Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature clinical 
practice. Oncology. 1, 39–43. 
Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., and Ferrara N. (1993). Inhibition of 
vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 
362, 841-4. 
Kitsukawa T., Shimono A., Kawakami A., Kondoh H., Fujisawa H. (1995). Overexpression of a membrane 
protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system 
and limbs. Development 121(12), 4309-18. 
Klagsbrun M, D'Amore PA. (1996). Vascular endothelial growth factor and its receptors. Cytokine Growth 
Factor Rev. 7(3), 259-70. 
Komori Y., Nikai T., Taniguchi K., Masuda K., Sugihara H. (1999). Vascular endothelial growth factor 
VEGF-like heparin-binding protein from the venom of Vipera aspis aspis (Aspic viper). Biochemistry 
38(36), 11796-803.  
Kriehuber E., Breiteneder-Geleff S., Groeger M., Soleiman A., Schoppmann S.F., Stingl G., Kerjaschki 
D., Maurer D. (2001). Isolation and Characterization of Dermal Lymphatic and Blood Endothelial 
Cells Reveal Stable and Functionally Specialized Cell Lineages. Journal of  Experimental Medicine 
194,  797 - 808.  
Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V., and Alitalo K. (1996). VEGF-C 
receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular 
development. Development 122(12), 3829-37 
Kärkkäinen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., Jeltsch M., Jackson D.G., 
Talikka M., Rauvala H., Betsholtz C., Alitalo K. (2004). Vascular endothelial growth factor C is 
required for sprouting of the first lymphatic vessels from embryonic veins. Nature immunology 5(1), 
74-80. 
Kärpänen T., Heckman C. A., Keskitalo S., Jeltsch M., Ollila H., Neufeld G., Tamagnone L., Alitalo K. 
(2006). Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. The FASEB 
Journal 20, 1462-1472. 
Kärpänen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., Alitalo K. (2001). 
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor 
growth. Cancer research 61(5), 1786-90. 
Leak L.V. (1976). The structure of lymphatic capillaries in lymph formation. Federation proceedings 35(8), 
1863-71. 
Lee J., Gray A., Yuan J., Luoh S.-M., Avraham H., and Wood,W. I. (1996). Vascular endothelial growth 
factor-related protein: A ligand and specific activator of the Tyrosine kinase receptor Flt4. 
Proceedings of the National Academy of Sciences of the United States of America 93, 1988-1992. 
Lehr R.V., Elefante L.C., Kikly K.K., O'Brien S.P., Kirkpatrick R.B. (2000). A modified metal-ion affinity 
chromatography procedure for the purification of histidine-tagged recombinant proteins expressed in 
Drosophila S2 cells. Protein expression and purification 19(3), 362-8. 
Lemmon M. A., and Schlessinger J. (1994). Regulation of signal transduction and signal diversity by receptor 
oligomerization. Trends in Biochemical Sciences 19, 459-63. 
Li X., Aase K., Li H., von Euler G., Eriksson U. (2001). Isoform-specific expression of VEGF-B in normal 
tissues and tumors. Growth Factors. 19(1), 49-59. 
Lu H. S., Hara S., Wong L. W., Jones M. D., Katta V., Trail G., Zou A., Brankow D., Cole S., Hu S., and 
et al. (1995). Post-translational processing of membrane-associated neu differentiation factor 
proisoforms expressed in mammalian cells. Journal of Biological Chemistry 270, 4775-83. 
Lyttle D.J., Fraser K.M., Fleming S.B., Mercer A.A., Robinson A.J. (1994). Homologs of vascular 
endothelial growth factor are encoded by the poxvirus orf virus. Journal of Virology 68(1), 84-92. 
Maglione D., Guerriero V., Viglietto G., Ferraro M. G., Aprelikova O., Alitalo K., DelVecchio S., Lei K. 
J., Chou J. Y., and Persico M. G. (1993). Two alternative mRNAs coding for the angiogenic factor, 
placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8, 
925-31. 
Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., and Persico M. G. (1991). Isolation of a human 
placenta cDNA coding for a protein related to the vascular permeability factor. Proceedings of the 
National Academy of Sciences of the United States of America 88, 9267-71. 
Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., 
Montesano R., Jackson D.G., Orci L., Alitalo K., Christofori G., Pepper M.S.. (2001). Vascular 
 64
endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO Journal 
20(4), 672-82. 
Marconcini L., Marchio S., Morbidelli L., Cartocci E., Albini A., Ziche M., Bussolino F., Oliviero S. 
(1999). c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo 
and in vitro. Proceedings of the National Academy of Sciences of the United States of America  96(17), 
9671-6. 
Matsumoto T., Claesson-Welsh L. (2001). VEGF receptor signal transduction. Sci STKE 2001(112), RE21. 
McClure C. 1908. The development of the thoracic and right lymphatic ducts in the domestic cat (Felis 
domestica). Anatomischer Anzeiger 32,  533-543. 
McColl B.K., Baldwin M.E., Roufail S., Freeman C., Moritz R.L., Simpson R.J., Alitalo K., Stacker S.A., 
Achen M.G.  (2003). Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. 
[Erratum in: J Exp Med. 2003 Oct 6;198(7):following 1126]. The Journal of experimental medicine 
198(6), 863-8.  
McDonald N. Q. and Hendrickson W. A. (1993). A structural superfamily of growth factors containing a 
cystine knot motif. Cell 73, 421-4. 
Mebius R.E. (2003). Organogenesis of lymphoid tissues. [Erratum in: Nat Rev Immunol.3(6):509.] Nature 
Reviews  Immunology 3(4), 292-303.  
Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, 
Rziha HJ, Dehio C. (1999). A novel vascular endothelial growth factor encoded by Orf virus, VEGF-
E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor 
tyrosine kinases. EMBO Journal 18(2), 363-74. 
Müller G., Behrens J., Nussbaumer U., Böhlen P., and Birchmeier W. (1987). Inhibitory action of 
transforming growth factor beta on endothelial cells. Proceedings of the National Academy of Sciences 
of the United States of America 84, 5600-4. 
Mäkinen T., Veikkola T., Mustjoki S., Karpanen T., Catimel B., Nice E.C., Wise L., Mercer A., Kowalski 
H., Kerjaschki D., Stacker S.A., Achen M.G., Alitalo K. (2001). Isolated lymphatic endothelial cells 
transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO 
Journal 20(17), 4762-73. 
Makinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., 
Jackson D.G., Kubo H., Nishikawa S., Yla-Herttuala S., Alitalo K. (2001). Inhibition of 
lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-
3. Nature Medicine 7(2), 199-205. 
Nakamura Y., Yasuoka H., Tsujimoto M., Yang Q., Imabun S., Nakahara M., Nakao K., Nakamura M., 
Mori I., Kakudo K. (2003). Flt-4-positive vessel density correlates with vascular endothelial growth 
factor-d expression, nodal status, and prognosis in breast cancer. Clinical Cancer Research  9, 5313-
17. 
Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., Shibuya M. (1998). A novel type of vascular 
endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and 
carries a potent mitotic activity without heparin-binding domain. Journal of Biological Chemistry 
273(47), 31273-82. 
Oliver G. and Alitalo K. (2005). The lymphatic vasculature: Recent progress and paradigms. Annual Review 
of Cell and Developmental Biology 21,  457-483.  
Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., Orpana A., Pettersson R. 
F., Alitalo K., and Eriksson U. (1996). Vascular endothelial growth factor B, a novel growth factor 
for endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 
93, 2576-81. 
O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. 
H., and Folkman J. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression 
of metastases by a Lewis lung carcinoma. Cell 79, 315-28. 
Orlandini M., Semboloni S., Oliviero S. (2003). Beta-catenin inversely regulates vascular endothelial growth 
factor-D mRNA stability. Journal of Biological Chemistry 278(45), 44650-6.  
Orlandini M., Oliviero S. (2001). In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by 
cadherin-11 Journal of Biological Chemistry 276(9), 6576-81.  
Orlandini M., Marconcini L., Ferruzzi R., Oliviero R. (1996). Identification of a c-fos-induced gene that is 
related to the platelet-derived growth factor/vascular endothelial growth factor family. 
Proceedings of the National Academy of Sciences of the United States of America 93(21), 11675-80. 
Erratum in: Proc Natl Acad Sci U S A 1997 Feb 18;94(4):1603. 
Oura H., Bertoncini J., Velasco P., Brown L.F., Carmeliet P., Detmar M. (2003). A critical role of 
placental growth factor in the induction of inflammation and edema formation. Blood. 101(2), 560-7.  
 65
Paavonen K., Puolakkainen P., Jussila L., Jahkola T., Alitalo K. (2000). Vascular endothelial growth factor 
receptor-3 in lymphangiogenesis in wound healing. American Journal of Pathology 156(5), 1499-504. 
Pajusola K., Aprelikova O., Pelicci G., Weich H., Claesson-Welsh L., Alitalo K. (1994).  Signalling 
properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF 
receptors. Oncogene 9(12), 3545-55 
Papoutsi M., Tomarev S.I., Eichmann A., Prols F., Christ B., Wilting J. (2001). Endogenous origin of the 
lymphatics in the avian chorioallantoic membrane. Developmental dynamics : an official publication 
of the American Association of Anatomists 222(2), 238-51 
Partanen T.A., Arola J., Saaristo A., Jussila L., Ora A., Miettinen M., Stacker S.A., Achen M.G., Alitalo 
K. (2000). VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in 
fenestrated blood vessels in human tissues. The FASEB journal : official publication of the Federation 
of American Societies for Experimental Biology14(13):2087-96. 
Partanen T.A., Alitalo K., Miettinen M. (1999). Lack of lymphatic vascular specificity of vascular 
endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86(11), 2406-12. 
Persico M.G., Vincenti V., DiPalma T. (1999). Structure, expression and receptor-binding properties of 
placenta growth factor (PlGF). Current topics in microbiology and immunology  237, 31-40.  
Plate K. (2001). From angiogenesis to lymphangiogenesis. Nature Medicine  7(2), 151-2. 
Pugh C.W. and Ratcliffe P.J. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nature 
medicine 9, 677-384.  
Randall D., Burggren W., French K. (2002). Eckert Animal Physiology: Mechanisms and Adaptations, Fifth 
Edition, Chapter 12: Circulation. (W.H. Freeman & Company) 
Ransone L.J., Wamsley P., Morley K.L., Verma I.M. (1990). Domain swapping reveals the modular nature 
of Fos, Jun, and CREB proteins. Molecular and cellular biology 10(9), 4565-73. 
Risau W.  (1997). Mechanisms of angiogenesis. Nature 386, 671-4. 
Risau W., Flamme I. (1995). Vasculogenesis. Annual review of cell and developmental biology 11, 73-91. 
Rissanen T.T., Markkanen J.E., Gruchala M., Heikura T., Puranen A., Kettunen M.I., Kholová I., 
Kauppinen R.A., Achen M.G., Stacker S.A., Alitalo K., Ylä-Herttuala S. (2003). VEGF-D is the 
strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via 
adenoviruses. Circulation research 92,  1098-106. 
Ristimaki A., Narko K., Enholm B., Joukov V., Alitalo K. (1998). Proinflammatory cytokines regulate 
expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. Journal of 
Biological Chemistry 273(14), 8413-8. 
Rocchigiani M., Lestingi M., Luddi A., Orlandini M., Franco B., Rossi E., Ballabio A., Zuffardi O., 
Oliviero S. (1998). Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 
between the PIGA and the GRPR genes. Genomics 47(2), 207-16. 
Rubin D.M., Mehta A.D., Zhu J., Shoham S., Chen X., Wells Q.R., Palter K.B. (1993). Genomic structure 
and sequence analysis of Drosophila melanogaster HSC70 genes. Gene  128(2), 155-63. 
Sabin F.R. (1902). On the origin of the lymphatic system from the veins and the development of the lymph 
hearts and thoracic duct in the pig. The American Journal of Anatomy 1, 367-391. 
Saleh M. Stacker S.A., Wilks A.F. (1996). Inhibition of growth of C6 glioma cells in vivo by expression of 
antisense vascular endothelial growth factor sequence. Cancer Research 56(2), 393-401 
Sambrook J., Fritsch E. F., and Maniatis T. (1989). Molecular cloning. A laboratory manual. (Cold Spring 
Harbor, NY: Cold Spring Harbor Laboratory Press). 
Sawano A., Iwai S., Sakurai Y., Ito M., Shitara K., Nakahata T., Shibuya M. (2001). Flt-1, vascular 
endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-
macrophages in humans. Blood 97(3), 785-91. 
Schneppenheim R, Budde U, Dahlmann N, Rautenberg P. (1991). Luminography--a new, highly sensitive 
visualization method for electrophoresis. Electrophoresis 12(5), 367-72. 
Schneppenheim R, Rautenberg P. (1987). A luminescence Western blot with enhanced sensitivity for 
antibodies to human immunodeficiency virus. European Journal of Clinincal Microbiology  6(1), 49-
51. 
Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., 
Kerjaschki D. (2002). Tumor-associated macrophages express lymphatic endothelial growth factors 
and are related to peritumoral lymphangiogenesis. Amercan Journal of  Pathology 161(3), 947-56. 
Schneider I. (1972). Cell lines derived from late embryonic stages of Drosophila melanogaster. Journal of 
embryology and experimental morphology 27(2), 353-65. No abstract available. 
Schneider M., Othman-Hassan K., Christ B., Wilting J. (1999). Lymphangioblasts in the avian wing bud. 
Developmental dynamics : an official publication of the American Association of Anatomists. 216(4-
5), 311-9. 
 66
Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. (1995). 
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535), 62-6. 
Shibuya M, Claesson-Welsh L. (2006). Signal transduction by VEGF receptors in regulation of angiogenesis 
and lymphangiogenesis.  Experimental Cell Research,  312(5), 549-60. 
Shibuya M. (2000). Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). 
The international journal of biochemistry & cell biology, 33(4), 409-20. 
Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., and Sato M. (1990). 
Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely 
related to the fms family. Oncogene 5, 519-24. 
Shida A, Fujioka S, Ishibashi Y, Kobayashi K, Nimura H, Mitsumori N, Suzuki Y, Kawakami M, 
Urashima M, Yanaga K. (2005). Prognostic significance of vascular endothelial growth factor D in 
gastric carcinoma. World journal of surgery 29(12),  1600-7. 
Siegfried G., Khatib A.M., Benjannet S., Chretien M., Seidah N.G. (2003). The proteolytic processing of 
pro-platelet-derived growth factor-A at RRKR(86) by members of the proprotein convertase family is 
functionally correlated to platelet-derived growth factor-A-induced functions and tumorigenicity. 
Cancer Reearch 63(7), 1458-63. 
Skobe M., Hamberg L.M., Hawighorst T., Schirner M., Wolf G.L., Alitalo K., Detmar M. (2001). 
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular 
endothelial growth factor-C in melanoma. Amercan Journal of  Pathology 159(3), 893-903. 
Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. (1998). Neuropilin-1 is expressed by 
endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 
92(6), 735-45. 
Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., 
Nishikawa S., Kubo H., Achen M.G. (2001). VEGF-D promotes the metastatic spread of tumor cells 
via the lymphatics. Nature Medicine 7(2), 186-91. 
Stacker S.A., Stenvers K., Caesar C., Vitali A., Domagala T., Nice E., Roufail S., Simpson R.J., Moritz 
R., Karpanen T., Alitalo K., Achen M.G. (1999). Biosynthesis of vascular endothelial growth factor-
D involves proteolytic processing which generates non-covalent homodimers. Journal of Biological 
Chemistry 274(45), 32127-36. 
Stone, E. J. and Hugo, N. E. (1972). Lymphedema. Surgery, gynecology & obstetrics  135, 625. 
Stupack DG, Cheresh DA. (2004). Integrins and angiogenesis. Current Topics in Developmental Biology 64, 
207-38.  
Takahashi H., Hattori S., Iwamatsu A., Takizawa H., Shibuya M. (2004). A novel snake venom vascular 
endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential 
signaling via VEGF receptor-1. Journal of Biological Chemistry 279(44), 46304-14.  
Terman B. I., Carrion M. E., Kovacs E., Rasmussen B. A., Eddy R. L., and Shows T. B. (1991). 
Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 1677-83. 
Tischer E., Mitchell R., Hartman T. (1991). The human gene for vascular endothelial growth factor: Multiple 
protein forms are encoded through alternative exon splicing. Journal of Biological Chemistry 266, 
11947-11954 
Thomas DM, Segaloff DL. (1994). Hormone-binding properties and glycosylation pattern of a recombinant 
form of the extracellular domain of the luteinizing hormone/chorionic gonadotropin receptor expressed 
in mammalian cells. Endocrinology 135(5), 1902-12. 
Thyboll J., Kortesmaa J., Cao R., Soininen R., Wang L., Iivanainen A., Sorokin L., Risling M., Cao Y., 
Tryggvason K.  (2002). Deletion of the laminin alpha4 chain leads to impaired microvessel 
maturation. Molecular cellular biology 22(4), 1194-202. 
Valtola R., Salven P., Heikkila P., Taipale J., Joensuu H., Rehn M., Pihlajaniemi T., Weich H., deWaal 
R., Alitalo K. (1999). VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast 
cancer. American Journal of Patholology 154(5), 1381-90. 
van der Geer P., Hunter T., and Lindberg R. A. (1994). Receptor protein-tyrosine kinases and their signal 
transduction pathways. Annual Review of Cell Biology 10, 251-337. 
Veikkola  T.,  Jussila  L.,  Makinen  T.,  Karpanen  T.,  Jeltsch  M.,  Petrova  T.V.,  Kubo  H.,  Thurston  G.,  
McDonald D.M., Achen M.G., Stacker S.A., Alitalo K. (2001). Signalling via vascular endothelial 
growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO Journal 
20(6):1223-31. 
Weindel K., Marme D., Weich H.A. (1992). AIDS-associated Kaposi's sarcoma cells in culture express 
vascular endothelial growth factor. Biochemical and biophysical research communications 183(3), 
1167-74. 
Von Heijne  G. (1986). A new method for predicting signal sequence cleavage sites. Nucleic acids research 
14(11), 4683-90. 
 67
Von Marschall Z., Scholz A., Stacker S.A., Achen M.G., Jackson D.G., Alves F., Schirner M., Haberey 
M., Thierauch K.H., Wiedenmann B., Rosewicz S. (2005). Vascular endothelial growth factor-D 
induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. 
IInternational journal of oncology 27,  669-79.   
Wang H.U., Chen Z.F., Anderson D.J. (1998). Molecular distinction and angiogenic interaction between 
embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 93(5), 741-53. 
Wigle J.T., Harvey N., Detmar M., Lagutina I., Grosveld G., Gunn MD., Jackson D.G., Oliver G..(2002). 
An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO 
Journal 21(7), 1505-13. 
Wigle J. and Oliver G. (1999). Function Is Required for the Development of the Murine Lymphatic System. 
Cell 98(6), 769-778 
Witte C.L. (2001). Pumps and lymphedema. Lymphology 34(4), 150-1. 
Witte M.H., Way D.L., Witte C.L., Bernas M. (1997). Lymphangiogenesis: mechanisms, significance and 
clinical implications. EXS 79, 65-112.   
Witte M. H., Bernas M. J., Martin C. P., Witte C. L. (2001). Lymphangiogenesis and lymphangiodysplasia: 
From molecular to clinical lymphology.  Microscopy Research and Technique 55(2), 122 – 145. 
Witzenbichler B., Asahara T., Murohara T., Silver M., Spyridopoulos I., Magner M., Principe N., 
Kearney M., Hu J.S., Isner J.M..,(1998). Vascular endothelial growth factor-C (VEGF-C/VEGF-2) 
promotes angiogenesis in the setting of tissue ischemia. American Journal of pathology 153(2), 381-
94. 
Wong S.Y., Haack H., Crowley D., Barry M., Bronson R.T., Hynes R.O. (2005). Tumor-secreted vascular 
endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but 
lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Research 65,  9789-98.  
Yamada Y., Nezu J., Shimane M., Hirata Y. (1997). Molecular cloning of a novel vascular endothelial 
growth factor, VEGF-D. Genomics.42(3), 483-8. 
Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., Holland C.M., Emoto M., 
Sakamoto A., Sakamoto T., Maruyama H., Sato S., Mizunuma H., et al. (20031). Expression of 
vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor 
in endometrial carcinoma. Clinical Cancer Research 9,  1361-9. 
Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., Holland C.M., Emoto M., 
Umemoto M., Sakamoto T., Sato S., Mizunuma H., Smith S.K. (20032) Vascular endothelial 
growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. British journal of 
cancer  88,  237-44. 
 
  
Internet addresses of the pictures and the software: 
 
Figure 1. http://www.embryology.ch/francais/pcardio/gefassegrundlage01.html #blutgefassentwicklung, 2006 
 
Figure 3. http://www.abpi.org.uk/publications/publication_details /targetbreastcancer/q&a5.asp, 2006 
 
Figure 4. http://www.med.unibs.it/~airc/angio2.gif, 2006 
 
Plasmid maps: Gene Construction KitTM  2.5, Texco Biosoftware Inc., 
http://www.textco.com/products/gck.html 
 
Protein purification control software: UNICORNTM 4.12, GE Healthcare, 
http://www.chromatography.amershambiosciences.com/aptrix/upp01077.nsf/Content/Products?OpenDocument
&parentid=5179&moduleid=6016&zone=Labsep 
 
 
 
 
 
 
 
 68
ACKNOWLEDGEMENTS 
The practical work for my master's thesis was carried out at the Biomedicum, 
Molecular/Cancer Biology Laboratory. I would like to thank: 
- Michael Jeltsch, my instructor, for being an outstanding example of a humble but still an 
ambitious scientist, and also for his wisdom, kindness and never-ending patience 
-     Tanja Laakkonen for her fantastic technical assistance 
- All members of the group for teaching me all I know and helping me in every possible way  
-     Punkerot for mental and physical coaching, on and off work 
- Team Otto and the whole Ryhtiryhmä for showing me how wonderful studying can be when 
you have the right people around you 
- AbFab for nothing less than being the best friends a girl can have 
- WRC Ladies for support (play) 
- Mom for always being there for me and Dad for believing in me 
- Tuomas for being my best friend, lover, and bodyguard.  
- And Kari Alitalo for giving me the opportunity to work in his group  
 
 
 I
 II
 III
 IV
 V
 VI
 VII
 VIII
 IX
 X
 XI
 XII
 XIII
 XIV
 XV
 XVI
 XVII
 XVIII
 XIX
 XX
 XXI
 
 
 
